Page last updated: 2024-08-23

paclitaxel and Cancer of Esophagus

paclitaxel has been researched along with Cancer of Esophagus in 463 studies

Research

Studies (463)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	30 (6.48)	18.2507
2000's	123 (26.57)	29.6817
2010's	212 (45.79)	24.3611
2020's	98 (21.17)	2.80

Authors

Authors	Studies
Chang, L; Jiang, L; Ke, Y; Liu, H; Liu, Y; Shi, X; Wang, C; Wang, J; Wang, S; Yang, D; Zhou, K	1
Dong, Y; Han, S; He, M; Huo, J; Ke, Y; Li, L; Li, Y; Liu, W; Liu, X; Pan, C; Qin, T; Shen, Y; Shi, X; Wang, C; Zhang, X; Zhao, J	1
Ba, Y; Bai, Y; Chen, Z; Cheng, Y; Fan, Q; Feng, J; Fu, Z; Gao, S; Gu, K; Huang, J; Li, J; Liu, Y; Liu, Z; Lu, J; Luo, H; Mao, T; Min, X; Niu, Z; Shen, Y; Wang, D; Wang, J; Wu, L; Xu, RH; Yang, Q; Zhang, H; Zhang, L; Zhang, X; Zhang, Y; Zhao, K; Zou, J	1
Chen, X; He, M; Li, D; Li, J; Li, X; Liu, Y; Zhang, X; Zhao, J; Zhao, L; Zhao, Y	1
Cloos-V Balen, M; Fiocco, M; Hartgrink, HH; Langers, AMJ; Lips, IM; Neelis, KJ; Peters, FP; Portier, ESH; Slingerland, M	1
Ba, Y; Feng, J; Liu, B; Liu, T; Pan, H; Qin, S; Qin, Y; Shen, L; Tanasanvimon, S; Voon, PJ; Xu, RH; Yang, N; Yin, X; Zhang, T; Zhang, WL; Zhang, Y; Zhou, C	1
Dong, Y; Han, S; He, M; Ke, Y; Li, L; Liu, X; Wang, C; Wang, Z; Zhao, J; Zhao, W	1
Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM	1
Chai, OH; Jin, H; Kim, SM; Meng, RY; Nguyen, TV; Park, BH	1
Huang, KL; Liu, J; Lv, L; Mo, JY; Wang, SC; Xu, ML	1
Bai, LY; Bai, Y; Chen, YY; Chen, Z; Chon, HJ; Chung, HC; Gu, K; Kang, YK; Koo, DH; Kuang, S; Lu, J; Park, YL; Qin, SK; Shih, CS; Shim, BY; Wan Ishak, WZ; Xu, J; Yuan, Y; Zeng, S; Zhong, WY	1
Chai, X; Fu, X; Gao, Q; Li, T; Liang, G; Lin, H; Liu, B; Liu, L; Liu, X; Ma, B; Qu, J; Ren, X; Shang, Y; Wang, Z; Xing, W; Yang, Y; Yuan, D; Zhang, H; Zhang, J; Zhang, Y; Zhao, L; Zheng, Y	1
Al-Jumayli, M; Al-Obaidi, A; Bansal, A; Baranda, J; Choucair, K; Park, R; Saeed, A; Sun, W	1
An, H; Bae, WK; Byun, JH; Han, HS; Jee, HJ; Kim, BJ; Kim, DS; Kim, JG; Lee, KW; Oh, DY; Park, SH; Rha, SY; Ryu, MH; Suh, YJ; Zang, DY	1
Anderson, CM; Crane, CH; Diaz Pardo, DA; DiPetrillo, T; Haddock, MG; Hong, TS; Ilson, DH; Kachnic, LA; Katz, AW; Leichman, LP; Leonard, KL; Mamon, H; Moughan, J; Rajdev, L; Resnick, M; Safran, HP; Salo, J; Seaward, S; Sharma, AK; Shen, X; Wigle, D; Winter, K	1
Capanu, M; Chalasani, SB; Chou, JF; Desai, AM; Greally, M; Ilson, DH; Janjigian, YY; Kelsen, DP; Ku, GY; Li, J; Moy, RH; Won, E	1
Barambo-Wagner, ML; Lohan-Codeço, M; Meireles Da Costa, N; Nasciutti, LE; Palumbo, A; Ribeiro Pinto, LF	1
Dong, X; Jia, Y; Song, X; Song, Y; Wang, W; Yi, Y; Zhang, J	1
Bai, C; Bai, Y; Chen, X; Cui, C; Cui, T; Dai, G; Fan, Q; Gao, Q; Gu, K; Huang, Y; Ji, S; Li, W; Li, Y; Liao, W; Liu, Y; Ma, D; Ma, Z; Mancao, C; Peng, B; Shu, Y; Sun, J; Tao, M; Wang, J; Wang, X; Wang, Y; Wu, L; Xiao, J; Xu, J; Xu, N; Yang, L; Yang, Y; Zhang, J; Zhang, T; Zhang, Y; Zhou, H	1
Ai, D; Cao, J; Du, M; Gu, D; Huang, G; Jia, H; Li, J; Li, L; Li, Y; Lin, Q; Luo, H; Mo, M; Wei, S; Yang, H; Ye, J; Zhang, Z; Zhao, K; Zhao, W; Zheng, X; Zhou, G; Zhou, J; Zhu, Z	1
Bei, T; Fang, Q; Han, Y; He, W; Huang, D; Leng, X; Liu, G; Luo, X; Mao, T; Peng, L; She, X; Shen, X; Wang, C; Wang, K; Wei, X; Xiao, W; Yan, J; Yi, H; Zhang, S; Zhang, X; Zhou, L	1
Gao, S; Lan, Z; Liang, G; Liu, Q; Qi, Y; Shi, R; Wang, H; Xu, J; Yang, T; Zhu, M	1
Han, Y; Wu, TT; Zhang, QL; Zhang, Y; Zheng, ZM	1
Gholamhosseinian, H; Iranshahy, M; Matin, MM; Mirzaei, S; Rassouli, FB	1
Du, M; Fang, Y; Gu, D; Li, H; Sun, L; Ye, J; Zhang, Z; Zhou, G	1
Chen, J; Chen, Y; Lin, YT; Liu, TX; Wang, C	1
Besnard, C; Guillerm, S; Hennequin, C; Quéro, L	1
Gibson, MK; Weidenbaum, C	1
Bonaventura, A; Day, F; Holt, B; Kumar, M; Loh, J; Lynam, J; Mandaliya, H; Martin, J; Smart, J; Sridharan, S	1
Chen, J; Dang, J; Li, S; Liu, T; Wang, H	1
Enzinger, PC; Guo, H; Joo, S; Meng, Y; Qu, T; Zhang, S; Zhong, Y	1
Ai, D; Bai, C; Chen, W; Du, M; Fang, Y; Gu, D; Li, H; Xu, X; Ye, J; Zhang, Z; Zhao, K; Zhou, G	1
Adams, A; Baues, C; Celik, E; Linde, P; Mallmann, M; Marnitz, S; Rosenbrock, J; Trommer, M; Wegen, S	1
He, J; Jia, L; Li, J; Li, Q; Li, X; Lin, P; Ren, Y; Shen, J; Shen, W; Shi, A; Wang, X; Wu, H; Wu, X; Wu, Y; Yang, J; You, J; Zhao, Y; Zhu, G; Zhu, S	1
Huang, JY; Huang, YY; Lin, X; Lin, ZX; Zhu, LH	1
Amanuma, Y; Arimitsu, Y; Chin, K; Kadowaki, S; Kanda, M; Kimura, Y; Kitagawa, Y; Kubota, Y; Nogi, Y; Okada, M; Takahashi, M; Yamamoto, S	1
Chen, X; Han, Y; Jiang, L; Leng, X; Peng, L; Wan, G; Wang, Q; Wang, Y; Wu, L; Zhu, J	1
Fang, R; Liu, Y; Wang, S; Xu, J	1
Ai, D; Chen, H; Chen, Y; Chu, L; Deng, J; Liu, Q; Ma, L; Miao, L; Shen, J; Xiang, J; Zhang, J; Zhang, X; Zhang, Y; Zhao, K	1
Chen, X; He, J; Kang, X; Li, H; Li, Y; Luo, P; Qin, J; Shen, Y; Wang, Z; Yang, Y; Zhang, R; Zheng, Q	1
Cui, X; Hu, Y; Jiao, S; Liu, M; Luo, H; Pan, C; Song, Z; Wu, D; Wu, L; Xu, Q; Yang, B; Yuan, J; Zhang, G; Zhang, J	1
Li, T; Li, XT; Li, XZ; Wang, XL; Wang, XW; Wang, XX; Yang, JC; Yang, ZY; Zhao, R; Zhao, XR	1
Cui, Y; Fan, X; Li, Y; Liu, C; Wu, K; Yang, Y; Yi, Q	1
Gao, J; Huang, J; Mu, L; Qi, L; Qu, T; Song, Y; Wang, X; Xin, D; Xu, J; Zhang, B	1
Chen, S; Chen, W; Cheng, C; Feng, S; Guo, F; Jiang, Z; Wang, H; Wang, Q; Wang, X; Wu, T; Xu, Z; Yang, S; Yang, W	1
Azuma, M; Fujii, M; Hihara, J; Ichikawa, W; Ishiguro, A; Izawa, N; Kadowaki, S; Katsuya, H; Kawabata, R; Kochi, M; Manaka, D; Michimae, H; Nagahisa, Y; Nakamura, M; Negoro, Y; Nishikawa, K; Sunakawa, Y; Suzuki, T; Takahashi, M; Takahashi, T; Tsuji, A	1
Benson, A; Burtness, BA; Catalano, P; Cohen, SJ; Crandall, TL; Dotan, E; Fisher, GA; Kumar, P; Lubner, SJ; Mitchell, EP; Mulcahy, MF; Stockton, S	1
Hirabayashi, T; Kushida, S; Miki, I; Mimura, T; Nishikawa, M; Takegawa, N; Tanaka, S; Tokuyama, N; Tsuda, M; Tsumura, H; Yamamoto, Y	1
Beyrer, JK; Chatterjee, A; Cui, ZL; Hadden, EL; Liepa, AM	1
Chao, YK; Cheng, YH; Chi, CL; Chuang, KH; Gao, X; van Lanschot, JJ; Wen, YW; Wu, CE; Yang, TY; Yang, ZH	1
Adams, KN; Ahmed, SJ; Akaputra, R; Akosman, I; Akya, A; Ali, S; Aminuddin, A; An, B; An, X; Anana, EV; Ao, L; Arany, Z; Arena, R; Azhar, A; Azhar, W; Baasankhuu, A; Bae, WK; Bahar, B; Balaji, L; Barbosa, M; Batchu, UR; Berg, KM; Berlin, N; Berthier, E; Bettiol, AA; Bi, B; Bodie, D; Borges, VF; Borghi-Silva, A; Bowman, CE; Brantly, M; Budhathoki, L; Bukhari, A; Cabeza, M; Cao, J; Cao, Q; Cao, S; Carrasco-Nuñes, N; Caruso, FR; Carvalho, C; Chakrabarty, D; Chandra Mondal, P; Chandran, V; Chang, P; Chase, M; Chauhan, AS; Chauhan, PS; Che, J; Cheemalamarri, C; Chen, D; Chen, H; Chen, J; Chen, Q; Chen, X; Chen, Z; Chetri, BK; Cho, SW; Choi, TI; Chung, HC; Cocchi, MN; Collins, LC; Colombo, N; Come, SE; Custodio, JM; Dai, TY; De La Garza Ramos, R; de Oliveira, CR; Dębczak, A; DeMuri, GP; Deng, J; Deng, K; Dhanani, LY; Diaz, S; Djaharuddin, I; Dong, G; Dong, Q; Donnino, MW; Dwiyanti, R; Elango, KP; Eleswarapu, A; Evans, EGB; Fachri, M; Fang, Y; Fantappiè, G; Farasat, A; Farsida, F; Fathimah, A; Febrianti, A; Feng, S; Fernandes, V; Fernandez Garcia, E; Fleming, GF; Foskett, JK; Fourman, MS; Fu, M; Fu, W; Fukushima, S; Gahlay, GK; Gai, S; Gao, R; Gao, W; Gilbert, DM; Gong, J; Gong, MN; Gong, Z; González-Cavieres, L; Gordon, SE; Goudarzi, F; Goulart, CDL; Greenstein, AE; Grigg, ARC; Grilli, D; Grisham, RN; Grossestreuer, AV; Grzęda, A; Grzegorczyk, A; Gu, J; Guo, H; Gupta, R; Haldar, A; Hamid, Y; Han, HJ; Hancock, CN; Hassan, GW; Hatta, M; He, D; He, F; He, J; Heidarinia, H; Helmchen, G; Herrera-Lavados, C; Hieber, DL; Hoehr, C; Hou, L; Huang, C; Huang, J; Hussain, S; Imaoka, S; Indoliya, Y; Jain, E; Jana, S; Jang, H; Jang, HS; Jara-Quijada, E; Jeacopello, I; Jeung, HC; Jiang, B; Jiang, D; Jiang, G; Jiang, L; Jiang, Q; Jiang, Y; Jiang, Z; Jiao, Z; Jr, JCB; Jung, M; Jung, S; Junita, AR; Kalavathi, A; Kang, X; Kannan, R; Kato, K; Khadka, M; Khan, AR; Khan, I; Khodayari, N; Kim, BJ; Kim, CG; Kim, CH; Kim, D; Kim, H; Kim, HS; Kim, HT; Kim, TS; Kim, YT; King, R; Koh, K; Konkol, M; Koo, DH; Kretzschmar, R; Krop, IE; Kuang, Y; Kubeneck, LJ; Kulkarni, K; Kumar, N; Kunjan, C; Kwon, WS; Lai, C; Lans, A; Lascano, J; Lavania, UC; Lee, CK; Lee, DA; Lee, HS; Lee, J; Lee, KH; Lee, MS; Lee, SW; Lee, UN; Lemus-Mondaca, R; Li, HR; Li, J; Li, Q; Li, X; Li, Y; Li, Z; Liang, H; Liang, Y; Lin, L; Lin, Y; Lipsyc-Sharf, M; Liu, B; Liu, C; Liu, DX; Liu, H; Liu, J; Liu, K; Liu, S; Liu, X; Liu, Z; Locknane, MP; Lorusso, D; Lü, H; Luo, Z; Lv, X; Ma, Y; Mandava, K; Manfrinetti, P; Mao, W; Marques-Sá, J; Masaki, T; Massi, MN; Matsuse, M; Matulonis, UA; Maxwell, CA; McAssey, EV; McManamen, AM; Mehl, RA; Mendes, RG; Meng, Z; Miao, Z; Miller, S; Milovanovic, S; Mishra, SK; Mitra, S; Mitsutake, N; Miyazaki, Y; Moriwaki, S; Mortenson, R; Moskowitz, A; Mudring, AV; Mues Genannt Koers, L; Muhammad, S; Muhimpundu, S; Murapaka, C; Murota, H; Mv, S; Nakazawa, Y; Nam, CM; Natzir, R; Ngo, L; Nguyen, DD; Nie, Y; Nishigori, C; Noji, MC; Notini, L; Oaknin, A; Ogi, T; Oguro, A; Okukawa, K; Olawaiye, AB; Omble, AD; Oso, T; Page, CA; Palma-Acevedo, A; Pani, M; Parikh, SM; Park, J; Park, S; Partridge, AH; Pashova, HI; Paudel, U; Paulssen, E; Payero, L; Peng, M; Peppercorn, JM; Pérez-Won, M; Pitarresi, JR; Pradhan, J; Prevost, D; Primaguna, MR; Puvvada, N; Qian, D; Rajaure, YS; Rajca, A; Rajput, N; Rana, SR; Rangan, L; Ranjbarian, P; Redd, PS; Ren, T; Rha, SY; Riley, L; Romano, M; Rong, X; Rosenberg, SM; Rostamian, M; Rothwell, KA; Ru, S; Ruddy, KJ; Rustgi, AK; Salam, A; Sankaran, S; Santoso, A; Saravanakumar, P; Satheeshkumar, K; Schapira, L; Schulz, K; Senapati, A; Senju, C; Sharma, P; Shelke, RG; Shen, F; Shen, X; Shen, Y; Sheteiwy, MS; Shetty, PR; Shi, L; Shi, MM; Shiigi, H; Shimada, M; Shinkawa, VAM; Shtender, V; Siswanto, FM; Smetana, V; Snow, C; Sridiana, E; Stephenson, MW; Stoll, S; Su, X; Sun, S; Sun, XF; Surapaneni, JR; Suri, K; Świątek, Ł; Syukri, A; Tabilo-Munizaga, G; Takezawa, MG; Tamimi, RM; Tamura, A; Tanaka, K; Tang, M; Tao, Y; Tateishi, S; Thapa, B; Theberge, AB; ThomasArrigo, LK; Thongpang, S; Tiwari, M; Tong, Q; Totton, RR; Tripathi, RD; Tsujimoto, M; Tu, WC; Tudor, IC; Tyskiewicz, K; Ubaidah, FM; Ulhassan, Z; Utani, A; Van Gorp, T; Veerapandian, V; Vennila, KN; von Gunten, U; Wagle, N; Waks, AG; Wald, ER; Wang, B; Wang, D; Wang, H; Wang, L; Wang, W; Wang, X; Wang, Y; Wang, Z; Warner, E; Waterhouse, GIN; Weiss, J; Weissenrieder, JS; Wellen, KE; Wu, JY; Xiang, W; Xiao, S; Xie, Q; Xu, F; Xu, TW; Xu, Y; Yan, B; Yan, JM; Yang, D; Yang, P; Yang, S; Yang, W; Yao, Y; Yassari, R; Yong, Q; Yu, H; Yu, Z; Yun, UJ; Zagotta, WN; Zang, DY; Zanudo, JGT; Zeng, A; Zhang, H; Zhang, R; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YT; Zhao, C; Zhao, J; Zhong, S; Zhou, F; Zhou, W; Zhou, Y	1
Cai, J; Cai, Y; Du, Q; Guo, X; Ma, Q; Xu, L; Yuan, Z; Zhong, X	1
Feng, Z; Han, R; Hu, B; Li, M; Wang, H; Zhang, R	1
Bi, G; Bian, Y; Feng, M; Hu, Z; Liang, J; Lu, T; Zhan, C; Zhao, M	1
Benedix, F; Croner, RS; Hass, P; Lorenz, E; Reinstaller, T; Weitz, A	1
Cai, XW; Fu, XL; Li, Y; Lin, L; Liu, J; Ma, XM; Song, XY; Yu, W; Zhang, Q; Zhao, SG	1
Khan, U; Shah, MA	1
Gu, J; Han, CC; Li, J; Liu, Y; Wang, C; Wang, H; Wang, M; Xia, Q; Xu, S; Zhang, N; Zhang, Z	1
Ajani, JA; Rogers, JE	1
Jiang, M; Mao, Y; Qi, S	1
Chen, J; Gu, W; Yao, H; Yin, W	1
Bennink, RJ; Biermann, K; Doukas, M; Gisbertz, SS; Krishnadath, KK; Lagarde, SM; Luyer, M; Meijer, SL; Neijenhuis, LKA; Nieboer, D; Nieuwenhuijzen, GAP; Nikkessen, S; Noordman, BJ; Oostenbrug, LE; Riedl, RG; Roef, MJ; Schoon, EJ; Sosef, MN; Spaander, MCW; Valkema, R; van Berge Henegouwen, MI; van der Gaast, A; van der Wilk, BJ; van Lanschot, JJB; van Lijnschoten, I; Wijnhoven, BPL	1
Chen, T; Chen, Y; Chen, Z; Cheng, N; Hu, Y; Hu, Z; Liu, D; Liu, Y; Wang, C; Wang, Z; Xu, Y; Yan, G; Yao, S; Zhang, T; Zhao, G	1
Al-Chamali, H; Bird, T; Cox, C; Dorey, N; Gomberg, S; Goody, R; Hingorani, M; Hurt, C; Macgregor, U; Mukherjee, S; Owens, R; Pan, S; Parikh, S; Prince, S; Radhakrishna, G	1
Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F	1
Beerepoot, LV; Bennink, RJ; Bijlsma, MF; Cats, A; Creemers, A; Creemers, GJ; Heisterkamp, J; Hospers, GAP; Hulshof, MCCM; Krishnadath, KK; Los, M; Mathôt, RAA; Meijer, SL; Molenaar, RJ; Nieuwenhuijzen, GAP; Punt, CJA; Schokker, S; Slingerland, M; Stroes, CI; van Berge Henegouwen, MI; van der Sangen, MJC; van der Woude, SO; van Laarhoven, HWM; van Oijen, MGH; Verhoeven, RHA	1
Boekhoff, MR; Borggreve, AS; Brosens, LAA; Goense, L; Heethuis, SE; Lagendijk, JJW; Meijer, GJ; Mook, S; Ruurda, JP; van Hillegersberg, R; van Lier, ALHMW; van Rossum, PSN	1
Boers, J; de Graaf, JC; de Groot, JWB; Joldersma, A; Pierik, EGJM; Schenk, BE; Timmer, PR; van Dalsen, AD; Wiegman, EM	1
Abgral, R; Amrane, K; Metges, JP; Querellou, S; Schick, U	1
Chen, YK; Hsu, YJ; Lee, MC; Lin, BR	1
Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D	1
Ajani, J; Al-Batran, SE; Bodoky, G; Cascinu, S; Cunningham, D; Ferry, D; Hozak, RR; Melemed, S; Muro, K; Oh, SC; Ohtsu, A; Sobrero, A; Van Cutsem, E; Wainberg, ZA; Wijayawardana, SR	1
Asari, R; Beer, A; Ilhan-Mutlu, A; Jomrich, G; Kristo, I; Paireder, M; Preusser, M; Rieder, E; Schmid, R; Schoppmann, SF	1
Boku, N; Esaki, T; Hironaka, S; Horie, Y; Hosokawa, A; Hyodo, I; Ishida, H; Kashiwada, T; Kawada, J; Makiyama, A; Moriwaki, T; Muro, K; Nishikawa, K; Shinozaki, K; Sukawa, Y; Tanioka, H; Tsuji, A; Tsukuda, H; Uchino, K; Yamanaka, T; Yamazaki, K; Yasui, H	1
Chen, H; Hong, J; Li, C; Lu, Q; Shi, B	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Blom, GJ; Bogers, JHA; Braam, PM; de Greef, BTA; de Jong, MA; de Vos-Geelen, J; Geurts, SME; Grabsch, HI; Hoeben, A; Hoebers, FJP; Hulshof, MCCM; Jeene, PM; Kasperts, N; Lemmens, VEPP; Muijs, CKT; Nieuwenhuijzen, GAP; Rozema, T; Tjan-Heijnen, VCG; van Dieren, JM; van Laarhoven, HWM; Voncken, FEM	1
Tian, S; Yao, N; Zhang, J	1
Li, J; Li, S; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X	1
Boekhoff, MR; Borggreve, AS; Defize, IL; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; Takahashi, N; van Hillegersberg, R; van Lier, ALHMW	1
Bang, YJ; Chung, HC; Iwasa, S; Kamio, T; Kawaguchi, Y; Kawakami, H; Kojima, A; Lee, J; Ryu, MH; Saito, K; Sakai, D; Shitara, K; Sugihara, M; Sugimoto, N; Yabusaki, H; Yamaguchi, K	1
Abraham, P; Gricar, J; Shankaran, V; Zhang, Y	1
Liu, H; Wei, W; Yao, Y; Yuan, J	1
Geng, X; Li, M; Wang, X; Zhang, Y; Zhao, Z; Zhu, L	1
Chan, FSY; Chan, WWL; Kwong, DLW; Lam, KO; Law, SYK; Wong, CLY; Wong, IYH; Zhang, RQ	1
Bian, X; Chen, M; Ding, L; Du, D; Hu, W; Jiang, W; Jing, Z; Li, D; Lian, X; Liu, Q; Luo, H; Ma, L; Tan, B; Wang, L; Wu, S; Xia, B; Xie, C; Xie, R; Zhang, H; Zheng, A	1
Bi, N; Chang, X; Deng, L; Deng, W; Feng, Q; Gao, LR; Han, W; Li, C; Li, L; Liang, J; Liu, W; Lv, J; Ni, W; Wang, J; Wang, W; Wang, X; Xiao, Z; Zhai, Y; Zhang, T; Zhao, Y; Zhou, Z	1
Beerepoot, LV; Creemers, GJ; de Vos-Geelen, J; Dijksterhuis, WPM; Haj Mohammad, N; Lemmens, VEPP; Pape, M; Slingerland, M; van Laarhoven, HWM; van Oijen, MGH; van Voorthuizen, T; Verhoeven, RHA	1
Adenis, A; Al-Rajabi, R; Bennouna, J; Bhagia, P; Chen, J; de la Fouchardiere, C; Doi, T; Enzinger, P; Ferreira, P; Francois, E; Girotto, G; Hsu, CH; Kang, SP; Kato, K; Kim, SB; Kojima, T; Lee, SH; Lordick, F; Metges, JP; Moriwaki, T; Muro, K; Qin, SK; Senellart, H; Shah, MA; Shen, L; Suryawanshi, S; Wang, R	1
Brar, S; Brierley, J; Chan, BA; Chen, EX; Darling, G; Elimova, E; Espin-Garcia, O; Hafezi-Bakhtiari, S; Jang, RW; Jiang, DM; Kim, J; Knox, JJ; Lim, CH; Liu, G; Moignard, S; Natori, A; Ringash, J; Rogalla, P; Sim, HW; Swallow, CJ; Wong, R	1
Chang Lee, R; Hsieh, AH; Moldovan, M; Price, T; Tomita, Y; Townsend, A	1
Barsky, AR; Ben-Josef, E; Dreyfuss, AD; Eads, JR; Karasic, TB; Kucharczuk, JC; Metz, JM; Plastaras, JP; Wileyto, EP; Williams, NN; Wojcieszynski, AP	1
Blom, GJ; Bogers, JA; Bouwense, SAW; Braam, PM; de Jong, MA; de Vos-Geelen, J; Geurts, SME; Hoebers, FJP; Jeene, PM; Kasperts, N; Muijs, CT; Nieuwenhuijzen, GAP; Rozema, T; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; Voncken, FEM	1
Abdel-Rahman, O; Easaw, J; Mulder, K	1
Amini, A; Chen, J; Chen, Y; Fan, M; Hamaji, M; Haque, W; Jeong, BK; Jia, H; Li, J; Li, L; Li, Y; Lin, Q; Lu, S; Mo, M; Nie, Y; Rivin Del Campo, E; Shridhar, R; Simone, CB; Tang, H; Wang, J; Wu, C; Wu, S; Xia, Y; Ye, J; Zhang, Z; Zhao, K; Zhao, W; Zhou, J; Zhu, H; Zhu, Z	1
Cai, HQ; Cai, Y; Cheng, ZJ; Du, GH; Fan, ZL; Hao, JJ; Liu, Z; Wang, D; Wang, JH; Wang, MR; Xu, X; Yang, LY; Zhang, N; Zhang, Y	1
Chen, C; Chen, KN; Dai, L; Du, M; Fang, Y; Gong, L; Hou, Y; Jiang, H; Jiao, J; Li, H; Li, K; Li, W; Li, Z; Lian, C; Liao, Y; Liu, J; Shen, Y; Tan, L; Tang, H; Wang, H; Wu, H; Xie, D; Yin, J; Zeng, Z; Zhao, Q; Zheng, B; Zhu, J	1
Kang, L; Li, C; Li, J; Xu, Z; Zhang, M; Zhao, J; Zhao, W	1
Beukema, JC; Blaisse, RJB; Bonenkamp, JJ; Busch, OR; Creemers, GM; Cuesta, MA; Eyck, BM; Hospers, GAP; Hulshof, MCCM; Nieuwenhuijzen, GAP; Piet, AHM; Plukker, JTM; Punt, CJA; Reinders, JG; Rozema, T; Shapiro, J; Spillenaar Bilgen, EJ; Steyerberg, EW; Ten Kate, FJW; Tilanus, HW; van Berge Henegouwen, MI; van der Gaast, A; van der Sangen, MJC; van der Wilk, BJ; van Hagen, P; van Laarhoven, HWM; van Lanschot, JJB; van Rij, CM; Verheul, HMW; Wijnhoven, BPL	1
Cooper, L; De León, LE; Dezube, AR; Dumontier, C; Enzinger, P; Frain, LN; Jaklitsch, MT; Kucukak, S; Mamon, H; Mazzola, E; Wee, JO	1
Chen, Y; Cheng, L; Cui, X; Du, X; Sheng, L; Zeng, J	1
Adelberg, D; Aurora-Garg, D; Bang, YJ; Caglevic, C; Cao, ZA; Chung, HC; Cristescu, R; Di Bartolomeo, M; Fuchs, CS; Kobie, J; Lu, J; Mandalà, M; Muro, K; Özgüroğlu, M; Ryu, MH; Shih, CS; Shitara, K; Van Cutsem, E	1
Buijsen, J; Geijsen, ED; Hulshof, MCCM; Jeene, PM; Neelis, KJ; Nuyttens, JJME; Oppedijk, V; Reinders, JG; Rozema, T; Thano, A; van Berge Henegouwen, MI; van der Gaast, A; van der Sangen, MJC; van Hooft, JE; van Laarhoven, HWM	1
Hopman, WM; Khalid, S; Virik, K	1
Fong, WP; Hu, M; Hu, Y; Li, Q; Li, Y; Ren, C; Tan, Q; Wang, D; Wang, Z; Wu, J; Yang, H	1
Li, Y; Lin, S; Shi, L; Yan, J	1
Chen, X; Lan, L; Liu, Y; Lu, B; Lu, Y; Mo, S; Wei, W; Wu, X; Zhang, F; Zhang, X	1
Fiocco, M; Grootenboers, DA; Marijnen, CA; Neelis, KJ; Peters, FP; Slingerland, M; van Ruler, MA; Vulink, AJ	1
Fang, M; Jia, Y; Li, J; Liang, X; Luo, L; Lv, S; Song, T; Xu, H	1
Anderegg, MCJ; Gisbertz, SS; Hulshof, MCCM; Los, M; Mohammed, NH; Ruurda, JP; van Berge Henegouwen, MI; van der Sluis, PC; van Hillegersberg, R; van Laarhoven, HWM; van Vulpen, M; Wiezer, MJ	1
Deng, W; Liu, J; Yue, J; Zhang, W; Zhang, Y	1
Dasanu, CA; Hyams, DM; Senatore, FJ	1
Bahadir, A; Erduran, E; Reis, GP; Sarihan, H; Yöney, A	1
Chang, L; Dou, Y; Huo, J; Liu, W; Qin, T; Shi, X; Wang, C; Wang, S; Yang, D; Yang, T; Zhou, K	1
Bensch, KG; Dolan, JP; Haisley, KR; Hart, KD; Hunter, JG; Nabavizadeh, N; Schipper, PH; Thomas, CR; Vaccaro, GM	1
Bueno, R; Catalano, PJ; Enzinger, PC; Hong, TS; King, BL; Mamon, HJ; Martin, NE; Sanford, NN; Wo, JY	1
Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y	1
Baeksgaard, L; Corkhill, AK; Crosby, T; Cuffe, S; Cunnane, M; Cunningham, M; Dermott, RM; Dib, M; Donohoe, CL; Griffin, SM; Hanna, G; Hennessy, B; Hofland, K; Illsley, M; Johnson, C; Jones, G; Lawner, P; Lee, K; Leonard, G; Marchesin, V; Mariette, C; Mellor, J; Muldoon, C; O'Dowd, G; O'Neill, B; O'Reilly, S; O'Toole, D; Parker, I; Preston, SR; Ravi, N; Reynolds, JV; Scott, K; Svendsen, LB; Warren, S	1
Chen, Z; Gao, J; Lai, Y; Li, Q; Li, Z; Liu, Z; Shen, L; Wang, J; Yuan, J	1
Al, MJ; Armstrong, N; Blommestein, HM; Büyükkaramikli, NC; Clay, FJ; Kleijnen, J; Riemsma, R; Ross, J; Severens, J; Worthy, G	1
Chen, T; Jing, Z; Wu, S; Zhang, X	1
Anker, CJ; Chakravarthy, AB; Crane, CH; Dicker, AP; Dubey, A; Giguere, J; Greenberger, JS; Horiba, N; Ilson, D; Kachnic, L; Konski, A; Pollock, J; Raben, A; Roof, K; Safran, H; Suntharalingam, M; Thakrar, H; Videtic, G; Winter, K	1
Bonnetain, F; Bosset, JF; Brain, E; Créhange, G; Mertens, C; Servagi-Vernat, S	1
Chen, X; Li, H; Lin, R; Su, M; Zhang, W; Zou, C	1
Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM	1
Hiranyatheb, P; Jiarpinitnun, C; Ngamphaiboon, N; Pattaranutaporn, P; Sirachainun, E; Supsamutchai, C; Tamtai, A; Unwanatham, N	1
Du, D; Fang, M; Song, T; Wu, S; Zhang, X	1
Anker, CJ; Francis, SR; Lloyd, S; Orton, A; Stoddard, G; Thorpe, C	1
Aird, JJ; Breathnach, OS; Gleeson, JP; Grogan, L; Herlihy, DB; Kay, EW; McNevin, CS; Morris, PG; Robb, WB	1
Fan, H; Li, J; Lu, P; Qin, Y; Xu, L	1
Bonenkamp, JJ; Cuesta, MA; Hulshof, MCCM; Lagarde, SM; Nieuwenhuijzen, GAP; Noordman, BJ; Plukker, JTM; Shapiro, J; Spillenaar Bilgen, EJ; Sprangers, MAG; Steyerberg, EW; van Berge Henegouwen, MI; van der Gaast, A; van Lanschot, JJB; Verdam, MGE; Wijnhoven, BPL	1
Beukema, JC; Biermann, K; Blaisse, RJB; Bonenkamp, JJ; Busch, OR; Creemers, GM; Cuesta, MA; Hospers, GAP; Hulshof, MCCM; Lagarde, SM; Nieuwenhuijzen, GAP; Noordman, BJ; Piet, AHM; Plukker, JTM; Punt, CJA; Reinders, JG; Rozema, T; Spillenaar Bilgen, EJ; Sprangers, MAG; Steyerberg, EW; Ten Kate, FJW; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van der Sangen, MJC; van Hagen, P; van Laarhoven, HWM; van Lanschot, JJB; van Rij, CM; Verdam, MGE; Verheul, HMW; Wijnhoven, BPL	1
Huo, J; Li, L; Liu, W; Qin, T; Shi, X; Wang, C; Yang, D; Zhang, X; Zhang, Y; Zhou, K	1
Bekaii-Saab, T; Sonbol, MB	1
Inoue, T; Kanazawa, A; Kodai, S; Kubo, N; Miura, K; Murata, A; Nishiguchi, Y; Nozawa, A; Sakurai, K; Shimizu, S; Tachimori, A; Tamamori, Y; Tauchi, J; Urata, Y; Yamashita, Y	1
Brunicardi, FC; Chen, S; Hou, Q; Jiang, M; Li, Y; Wang, C; Wu, H; Wu, S; Yang, L; Yu, J; Zhang, H; Zhang, XY	1
Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van Hillegersberg, R; van Rossum, PSN; Verhoeven, RHA; Visser, E	1
Adenis, A; Lordick, F	1
Liu, J; Yue, J	1
Ilson, D; Suntharalingam, M; Winter, K	1
Hassan, MS; von Holzen, U	1
Hendriksen, EM; Hoekstra, R; Kouwenhoven, EA; Kreuger, MJ; Lubbers, M; van Det, MJ; Vermeer, M	1
Chen, T; Dong, X; Li, Y; Ma, H; Meng, X; Qi, D; Su, J; Wang, W; Yang, L; Zhang, X	1
Chakrabarti, S; Dong, H; Paripati, HR; Ross, HJ; Yoon, HH	1
Aigner, T; Göbel, H; Grabenbauer, GG; Leibl, B; Vitz, S	1
Petty, RD; Smyth, EC	1
Bang, YJ; Caglevic, C; Chen, X; Chung, HC; Di Bartolomeo, M; Fornaro, L; Fuchs, CS; Goekkurt, E; Kang, SP; Mandalà, M; Mansoor, W; Mayo, C; McDermott, RS; Muro, K; Ohtsu, A; Olesiński, T; Özgüroğlu, M; Ryu, MH; Shacham-Shmueli, E; Shitara, K	1
Doosti-Irani, A; Haddad, P; Holakouie-Naieni, K; Mansournia, MA; Rahimi-Foroushani, A	1
Adams, O; Berezowska, S; Dislich, B; Feith, M; Humbert, M; Janser, FA; Kroell, D; Langer, R; Ott, K; Seiler, CA; Slotta-Huspenina, J; Tschan, MP	1
Al-Batran, SE; Alsina, M; Bang, YJ; Boku, N; Chung, HC; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, KW; Lichinitser, M; Moehler, MH; Park, SH; Ruiz, EY; Ryu, MH; Schenker, M; Taieb, J; Van Cutsem, E; Wyrwicz, L; Xiong, H	1
Dai, CL; Dai, SB; Han, GH; Huang, JX; Lu, KJ; Zhang, LX	1
Cao, M; Gao, Q; Ji, Y; Li, S; Peng, T; Wang, G; Zhang, Y	1
Aitken, K; Athauda, A; Chau, I; Cunningham, D; Mohammed, K; Rao, S; Starling, N; Tait, D; Watkins, D	1
Ai, D; Badakhshi, H; Cao, J; Chen, Y; Deng, J; Fan, J; Fan, M; Huang, G; Li, J; Li, L; Li, Y; Lin, Q; Liu, Q; Luo, H; Ren, W; Wei, S; Wu, K; Yang, H; Ye, J; Zhang, J; Zhao, K; Zhao, W; Zheng, X; Zhou, J; Zhu, H; Zhu, Z	1
Li, R; Liu, B; Qian, H; Ren, W; Sha, H; Wu, P; Yan, J; Yang, J; Yu, L; Zhang, H	1
Chen, Y; Elliott, DA; Holland, JM; Kusano, A; Mitin, T; Nabavizadeh, N; Rana, SR	1
Diao, P; Lang, J; Li, C; Li, F; Li, T; Liu, L; Lyu, J; Wang, Q	1
Cheng, AL; Chia-Hsien Cheng, J; Hsu, CH; Hsu, FM; Huang, PM; Huang, TC; Lee, JM; Lin, CC; Tzen, KY; Wang, HP; Wu, YC; Yeh, KH	1
Chen, Q; Fan, Y; Gong, L; Jiang, Y; Mao, W	1
Dong, Y; Grimm, R; Guo, J; Jiang, L; Kamel, IR; Li, H; Lu, Y; Qin, J; Qu, J; Wang, Z; Yan, X; Zhang, F; Zhang, H; Zhang, S; Zhang, T; Zhang, Z; Zhao, Y	1
Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G	1
Beitler, JJ; Cardin, D; Cardona, K; Chakravarthy, AB; Chen, Z; El-Rayes, BF; El-Rifai, W; Fernandez, F; Force, S; Goff, L; Harvey, RD; Higgins, K; Krasinskas, A; Lambright, E; Landry, J; Nesbitt, J; Owonikoko, T; Pickens, A; Ramalingam, SS; Saba, NF; Salaria, S; Shin, DM; Staley, C; Willingham, F	1
Ajani, JA; Amlashi, FG; Blum Murphy, MA; Elimova, E; Rogers, JE; Sanders, E; Shanbhag, N; Thomas, I; Xiao, L	1
Ambarus, CA; Menting, SP; van den Ende, T; van Laarhoven, HWM; van Oijen, MGH	1
Chen, Y; Fan, M; Jia, H; Li, J; Li, L; Li, Y; Lin, Q; Lu, S; Tang, H; Wu, C; Xia, Y; Ye, J; Zhang, Z; Zhao, K; Zhao, W; Zhou, J; Zhu, Z	1
Bennink, RJ; Bijlsma, MF; Creemers, A; Ebbing, EA; Hulshof, MCCM; Jibodh, RA; Krishnadath, KK; Medema, JP; Meijer, SL; Punt, CJA; Steins, A; van Delden, OM; van der Zalm, AP; van Laarhoven, HWM; Waasdorp, C	1
Doyle, SL; Elliott, JA; Foley, G; Guinan, EM; King, S; Murphy, CF; O'Byrne, L; Ravi, N; Reynolds, JV	1
Zhao, K	1
Adenis, A; Conroy, T; Crehange, G	1
de Castria, TB; Fujiki, FK; Hoff, PMG; Takeda, FR; Victor, CR	1
Fan, QX; Wang, XJ; Zhang, XD; Zheng, YL	1
Gong, Y; Liu, Y; Peng, F; Sun, L; Tu, L; Wang, Y; Wei, Y; Xu, Y; Zhou, L; Zhu, J	1
Almhanna, K; Chuong, MD; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Weber, JM	1
Chen, J; Chen, M; Li, J; Liao, Z; Liu, J; Pan, J; Zheng, X; Zhu, K	1
Bains, MS; Gerber, N; Goodman, KA; Ilson, DH; Janjigian, YY; Kelsen, DP; Rizk, N; Rusch, VW; Wu, AJ; Zhang, Z; Zheng, J	1
Beukema, JC; Burgerhof, JG; Güler, S; Hospers, GA; Mul, VE; Plukker, JT; Smit, JK	1
Guo, LB; Li, YM; Liu, HM; Ma, JY; Wang, C	1
Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH	1
Biermann, K; Shapiro, J; ten Kate, FJ; van Hagen, P; van Lanschot, JJ; Wijnhoven, BP	1
Beukema, JC; Bosch, DJ; Burgerhof, JG; Hospers, GA; Muijs, CT; Mul, VE; Plukker, JT	1
Chen, J; Fan, PS; He, YF; Hu, B; Hu, CL; Ji, CS; Jiang, FS; Wang, W; Yao, YW; Zhu, L	1
Kim, SM; Lee, HH; Lee, KB; Li, XJ; Park, MH; Ye, S	1
Danno, K; Fujitani, K; Fukui, A; Iwase, K; Kawada, J; Kubota, M; Matsuda, C; Matsui, Y; Nishikawa, K; Nishimura, M; Noguchi, Y; Nomura, M; Okumura, Y; Omori, K; Takagi, M; Tanaka, Y	1
Beukema, J; Hospers, G; Karrenbeld, A; Kluin, P; Langendijk, J; Muijs, C; Mul, V; Plukker, J; Smit, J; van Dam, G	1
Beukema, JC; Hulshof, MC; Oppedijk, V; Reinders, JG; Richel, DJ; Rütten, H; Spruit, PH; van Berge Henegouwen, MI; van der Gaast, A; van der Sangen, MJ; van Hagen, P; van Lanschot, JJ; van Os, R; van Rij, CM	1
Hulshoff, JB; Plukker, JT; Smit, JK; van der Jagt, EJ	1
Bergman, JJ; Geijsen, D; Haj Mohammad, N; Hulshof, MC; van Berge Henegouwen, MI; van Laarhoven, HW; Wilmink, JW	1
Beukema, JC; Burgerhof, JGM; de Groot, JW; Fiets, WE; Honing, J; Hospers, GAP; Legdeur, MJC; Muijs, CT; Muller, K; Paardekooper, G; Plukker, JTM; Slot, A; Smit, JK; Woutersen, D	1
Bosch, DJ; Hospers, GA; Mul, VE; Plukker, JT; Van Dalfsen, QA	1
Chen, L; Chen, Y; Fan, N; Guo, Z; Lin, J; Lin, R; Wang, X; Yu, J	1
Chen, J; Feng, Y; Liu, Y; Shao, N; Wang, Y; Zhang, L	1
Castaneda, L; Chang, DT; Cheng, JC; Graber, MS; Hsu, FM; Koong, AC; Lee, JM; Tsai, CL	1
Geijsen, ED; Hulshof, MC; van Berge Henegouwen, MI; van Hooft, JE; van Laarhoven, HW; van Os, RM; Versteijne, E	1
An, SM; Badakhshi, H; Chen, Y; Deng, JY; Guo, XM; Jiang, GL; Ma, HF; Tang, HR; Zhang, JH; Zhang, Z; Zhao, KL	1
Chen, J; Chen, M; Li, J; Lin, Y; Liu, J; Pan, C; Pan, J; Zhu, K	1
Arnould, L; Bonnetain, F; Borg, C; Cleau, D; El Gani, M; Fein, F; Fratté, S; Ghiringhelli, F; Jacquin, M; Jary, M; Kim, S; Lamfichekh, N; Lassabe, C; Mathieu, P; Nerich, V; Nguyen, T; Paget-Bailly, S; Valmary-Degano, S	1
Boggs, DH; Burrows, W; Hanna, A; Horiba, N; Morris, CG; Suntharalingam, M; Tarabolous, C	1
Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J	1
Cai, XY; Chen, XX; Guo, GF; He, WZ; Jiang, C; Liao, FX; Qiu, HJ; Rong, YM; Xia, LP; Yang, Q; Yin, CX; Zhang, B	1
Barthet, M; Gonzalez, JM; Vanbiervliet, G	1
Bergman, JJ; Hulshof, MC; Kapiteijn, E; Klinkenbijl, JH; Kordes, S; Meijer, SL; Richel, DJ; van Berge Henegouwen, MI; van der Vliet, HJ; van Laarhoven, HW; Wilmink, JW	1
Du, J; Hu, B; Hu, C; Wang, F; Zhang, Y	1
Ajani, J; Bodoky, G; Carlesi, R; Chandrawansa, K; Cunningham, D; Emig, M; Ferry, D; Hironaka, S; Kim, TY; Komatsu, Y; Lipatov, O; Muro, K; Oh, SC; Ohtsu, A; Rougier, P; Schwartz, JD; Shimada, Y; Sugimoto, N; Van Cutsem, E; Wilke, H	1
Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y	1
Chen, G; Peng, J; Song, Y; Tao, G; Wang, W; Zhou, X; Zhu, W	1
Fan, Q; Shi, Y; Wang, X; Zhang, X; Zheng, Y	1
Feng, W; Liuxing, W; Qingxia, F; Ran, Z; Xiangke, L; Xiaoyan, X; Xuan, Y; Zichang, Y	1
Bel, A; Bergman, JJ; Boekholdt, SM; de Bruin-Bon, HA; Geijsen, ED; Gisbertz, SS; Haj Mohammad, N; Hulshof, MC; Kamphuis, M; Lutkenhaus, LJ; van Laarhoven, HW	1
Amani, M; Broucek, M; Monga, V; Ramaswamy, S	1
Lu, WB; Ni, XC; Sun, SP; Sun, ZQ; Wang, J; Wang, JL; Yu, JP	1
Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M	1
Li, QL; Qiu, MQ; Wang, T; Yang, JS	1
Hurkmans, CW; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ	1
Chen, W; Guo, S; Li, J; Liu, J; Shen, Y; Wang, Z; Wu, K	1
Chen, KN; Chen, Y; Fan, MY; Li, XT; Liang, Z; Sun, Y; Sun, YS; Wang, ZL; Wu, Y; Xiong, HC; Yan, WP; Zhang, XY	1
Akhtar, J; Wang, S; Wang, Z	1
Dolan, JP; Elliott, DA; Holland, JM; Hunter, JG; Maggiore, RJ; Mitin, T; Nabavizadeh, N; Schipper, PH; Shukla, R; Thomas, CR; Vaccaro, GM	1
Casak, SJ; Chen, H; Dougherty, M; Fashoyin-Aje, I; He, K; Helms, W; Jin, R; Keegan, P; Kennett, S; Khasar, S; Lemery, SJ; Li, H; Novak, R; Pazdur, R; Zhang, H; Zhang, L; Zhao, H; Zhao, L	1
Berbée, M; Buijsen, J; Houben, R; Janssen, L; Lambin, P; Larue, R; Schraepen, MC; Sosef, M; Van De Voorde, L; Vanneste, B	1
Chen, S; Chen, X; Ding, Y; Li, Y; Mo, K; Mo, X; Yang, S; Zhang, F	1
Feng, JE; Mei, JF; Shen, B; Shi, L; Yuan, Y; Zhang, Y	1
Chen, HX; Wang, Z	1
Hsu, CH; Huang, TC; Lin, CC; Tu, YK	1
Beukema, JC; Biermann, K; Bilgen, EJS; Blaisse, RJB; Bonenkamp, JJ; Busch, ORC; Creemers, GM; Cuesta, MA; Hospers, GAP; Hulshof, MCCM; Nieuwenhuijzen, GAP; Piet, AHM; Plukker, JTM; Punt, CJA; Reinders, JG; Rozema, T; Shapiro, J; Steyerberg, EW; Ten Kate, FJW; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van der Sangen, MJC; van Hagen, P; van Laarhoven, HWM; van Lanschot, JJB; van Rij, CM; Verheul, HMW; Wijnhoven, BPL	1
Dai, Z; Kang, H; Min, W; Ren, H; Sui, X; Wang, XJ; Zhang, Y; Zhao, Y	1
Carlesi, R; Chandrawansa, K; Chao, Y; Cheng, R; Cho, JY; Lee, KW; Muro, K; Oh, SC; Ohtsu, A; Orlando, M; Shimada, Y; Yen, CJ	1
Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y	1
Greig, SL; Keating, GM	1
Anderegg, MC; Gisbertz, SS; Hulshof, MC; Lagarde, SM; Meijer, SL; Spierings, LE; van Berge Henegouwen, MI; van Laarhoven, HW; van Oijen, MG; Wilmink, JW	1
Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M	1
Cui, Y; Gao, J; Gong, J; Jia, J; Li, J; Li, Y; Liu, C; Lu, M; Lu, Z; Shen, L; Sun, Z; Wang, X; Yu, J; Zhang, X; Zhou, J	1
Im, YH; Kim, M; Kim, S; Lee, J; Lee, SJ; Park, SH; Park, YH	1
Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y	1
Chen, D; Duan, C; Huang, C; Lai, L; Wang, L; Yang, X	1
Chen, KN; Dong, B; Lin, Y; Shen, LY; Shi, Q; Wang, H; Yan, WP	1
Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyanaga, S; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T	1
Al-Batran, SE; Bodoky, G; Chandrawansa, K; Cunningham, D; Emig, M; Hironaka, S; Kim, TY; Liepa, AM; Lipatov, ON; Muro, K; Oh, SC; Ohtsu, A; Rougier, P; Shimada, Y; Sugimoto, N; Van Cutsem, E; Wilke, H	1
Jiang, D; Sun, DY; Xie, ZY; Zhao, YG; Zhou, MH; Zhu, HW	1
Gong, J; Jia, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Zhang, X; Zhou, J	1
Ebisui, C; Fukuchi, N; Kinuta, M; Murata, K; Nushijima, Y; Okada, K; Okamura, S; Yanagisawa, T; Yokouchi, H	1
Chien, AJ; Cockerill, A; Esserman, LJ; Fancourt, C; Kelley, RK; Ko, AH; Korn, WM; Melisko, ME; Moasser, MM; Munster, PN; Rugo, HS; Schmidt, E; van't Veer, L; Wolf, DM; Yau, C	1
Qin, RQ; Wang, WP; Wen, YS; Xi, KX; Yu, XY; Zhang, LJ	1
Anne, PR; Benson, AB; Catalano, PJ; Forastiere, AA; Keller, SM; Kleinberg, LR; Mitchel, EP	1
Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ	1
Chikamatsu, S; Imai, H; Ishioka, C; Kasahara, Y; Kobayashi, A; Komine, K; Oishi, T; Okada, Y; Okita, A; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S	1
Ghosh-Laskar, S; Jambhekar, N; Joshi, A; Mahajan, A; Mehta, SA; Nakti, D; Noronha, V; Patil, PS; Patil, VM; Prabhash, K; Purandare, N; Sahu, A; Shah, S; Talole, S	1
Creemers, GJ; Kathiravetpillai, N; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ	1
Chen, KN; Chen, Y; Li, XT; Sun, YS; Wang, ZL	1
Adenis, A; Clisant, S; Dahan, L; El Hajbi, F; Glehen, O; Kramar, A; Lacornerie, T; Mariette, C; Messager, M; Mirabel, X; Paumier, A; Piessen, G; Robb, WB; Tresch, E; Vasseur, F; Vendrely, V	1
Iranshahi, M; Matin, MM; Rassouli, FB; Saboor-Maleki, S	1
Chen, Q; Fan, Y; Gong, L; Huang, Z; Jiang, Y; Lei, T; Liu, J; Mao, W; Xu, Y; Yang, H; Yu, H; Zhao, Q; Zhou, X	1
Chen, YS; Li, K; Liu, Y; Qiao, L; Wu, XY; Xu, SN; Yuan, L	1
Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q	1
van der Woude, SO; van Laarhoven, HW	1
Garrido, M	1
Fan, R; He, C; Jiang, Q; Liu, J; Liu, R; Zhang, J	1
De Rooij, S; Erdkamp, F; Gisbertz, S; Haj Mohammad, N; Hulshof, M; Ruurda, J; Sosef, M; Sprangers, M; van Berge Henegouwen, M; van Laarhoven, H; Wijnhoven, B	1
Bergmann, JJ; Geijsen, ED; Hulshof, MC; Jeene, PM; Muller, K; van Berge Henegouwen, MI; van Laarhoven, HW; Versteijne, E	1
Cheng, SY; Du, J; Li, J; Li, KC	1
Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP	1
Chen, Y; Ge, F; Jia, R; Jin, Y; Lin, L; Liu, J; Liu, R; Wang, Y; Xu, J; Zhao, C	1
Banavali, S; Chougule, A; Joshi, A; Noronha, V; Patil, VM; Prabhash, K	1
Han, X; Lu, N; Pan, Y; Xu, J	1
Hazama, S; Iida, M; Kanekiyo, S; Kitahara, M; Nagano, H; Nishiyama, M; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Ueno, T; Yamamoto, S; Yoshino, S	1
Dou, Y; Guo, L; Ke, Y; Li, Y; Liu, H; Shi, H; Wang, C; Wang, J; Wang, R; Wang, S	1
Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U	1
Chen, J; Fan, Z; Huang, J; Ma, L; Shuang, J; Zhang, Y	1
Cats, A; Jansen, EP; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; Voncken, FE	1
Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M	1
Ajani, JA; Bradley, J; Fromm, M; Hornback, D; Kelsen, DP; Komaki, R; Liao, Z; Minsky, BD; Willett, CG; Winter, K	1
Bader, FG; Becker, K; Busch, R; Fink, U; Hofler, H; Lordick, F; Ott, K; Siewert, JR	1
Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG	1
Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T	1
Bartelsman, JF; Busch, OR; Koning, CC; Koppert, LB; Muller, K; Offerhaus, GJ; Richel, DJ; Steyerberg, EW; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van Heijl, M; van Lanschot, JJ; Wijnhoven, BP	1
Gong, Y; Hou, M; Huang, M; Lu, Y; Ren, L; Wang, J; Wei, Y; Zhou, L; Zhou, X; Zhu, J	1
Jiang, YY; Sun, CC; Wang, J; Wu, SX; Xie, CY; Zhang, P	1
DuVall, GA; Elstad, NL; Fowers, KD; Seidel, RH; Tarabar, D	1
Crezee, J; Fockens, P; Geijsen, ED; Hulshof, MC; Oldenborg, S; Richel, DJ; Van Berge Henegouwen, MI; Van Haaren, PM; Van Lanschot, JJ	1
de Hingh, IH; Gosens, MJ; Hendriks, T; Nienhuijs, SW; Nieuwenhuijzen, GA; Rieff, EA; Rutten, HJ; van den Brule, AJ	1
Liu, C; Shen, W; Sun, Q; Wang, D; Xu, H; Zhong, B; Zhong, H	1
Lv, L; Song, B; Song, X; Wang, X; Wei, L; Xie, L; Yu, J	1
Cao, W; Geng, M; Jiang, J; Jin, Y; Li, H; Lou, G; Xi, W; Xu, C; Zhao, S	1
Honova, H; Kralova, D; Pazdro, A; Pazdrova, G; Petruzelka, L; Smejkal, M; Zemanova, M	1
Boonstra, JJ; Koppert, LB; Tilanus, HW; Tran, TC; Van Dekken, H; Van der Gaast, A; Wijnhoven, BP	1
Aguero, EG; Garrett-Mayer, E; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Wahlquist, AE; Watkins, JM	1
Hara, T; Hiramatsu, K; Hosoya, J; Ito, T; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Maeda, T; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T	1
Deng, X; Hu, W; Li, G; Wang, J; Wu, S; Xie, C; Zhang, P; Zhang, X	1
Adler, G; Eisele, M; Galle, PR; Kaechele, V; Klaus, J; Lutz, MP; Moehler, M; Seufferlein, T; von Wichert, G	1
Balkissoon, J; Boxall, J; Chaplin, DJ; Ganesan, TS; Gaya, A; Nathan, PD; Poupard, L; Rustin, GJ; Shreeves, G; Stratford, MR; Wang, D; Zweifel, M	1
Aurilio, G; Catalano, G; Ciardiello, F; De Vita, F; Del Genio, A; Di Martino, N; Galizia, G; Lieto, E; Martinelli, E; Morgillo, F; Napolitano, V; Orditura, M; Pacelli, R; Vecchione, L	1
Aleman, BM; Boot, H; Cats, A; Courrech Staal, EF; Jansen, EP; van Coevorden, F; van Sandick, JW; van Velthuysen, ML	1
Huang, Y; Li, LB; Lin, XD; Lin, XY; Shi, X; Wang, RX; Zhang, ZF; Zheng, H	1
Amano, N; Hamamoto, Y; Hironaka, S; Imamoto, H; Kato, K; Muro, K; Seriu, T; Tahara, M; Takiuchi, H	1
An, HY; Cao, XF; Ji, L; Lü, J; Tao, L; Wang, DD; Wang, S; Wu, BC; Zhu, B	1
Aklilu, M; Blackstock, AW; Clark, P; Geisinger, KR; Isom, S; Levine, EA; Mishra, G; Monjazeb, AM; Riedlinger, G	1
Wang, L; Wang, T; Zhang, SF	1
Bergman, JJ; Boellaard, R; Bonenkamp, HJ; Bossuyt, PM; Busch, OR; Cuesta, MA; Hoekstra, OS; Hulshof, MC; Nieuwenhuijzen, GA; Omloo, JM; Plukker, JT; Pruim, J; Sloof, GW; Ten Kate, FJ; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van Heijl, M; van Lanschot, JJ	1
Battafarano, R; Birnbaum, A; Burrows, W; Dipetrillo, T; Fontaine, J; Horiba, N; Ng, T; Oldenburg, N; Perez, K; Safran, H; Suntharalingam, M	1
Chen, JS; Cheng, JC; Chuang, TH; Hsu, CH; Hsu, HH; Huang, PM; Kuo, SW; Lee, JM; Lee, YC; Lin, CC; Shun, CT; Wang, YH; Wu, MT; Yang, PW; Yang, SY	1
Ajani, JA; Hofstetter, WL; Komaki, RU; Konski, AA; Swisher, SG; Willett, CG; Winter, KA; Wu, TT	1
Chia-Hsien Cheng, J; Hsu, CH; Hsu, FM; Huang, PM; Lee, JM; Lee, YC; Lin, CC; Tsai, YC	1
Ciardiello, F; De Vita, F; Di Martino, N; Galizia, G; Lieto, E; Martinelli, E; Morgillo, F; Orditura, M; Pacelli, R; Renda, A; Vitiello, F	1
Choi, HL; Han, JY; Kim, HT; Kim, HY; Lee, JS; Nam, BH; Yun, T	1
Chung, MJ; Kim, B; Kim, JS; Kim, SH; Kim, SJ; Kim, SM; Kim, SZ; Lee, JS; Park, WH	1
Fujiwara, H; Hosoi, N; Koeda, K; Konosu, M; Sase, M; Taguchi, M; Tamasawa, Y; Tsukahara, T; Ushio, A; Wakabayashi, G	1
Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T	1
Inoue, S; Miyata, M; Ohashi, I; Takami, K; Tamura, C; Wakasa, T	1
Ansari, R; Fisher, W; Hanna, N; Koneru, K; Liu, Z; McClean, J; Robin, E; Schmitt, JM; Sommers, SR; Tong, Y	1
Chen, Q; Chen, Y; Deng, W; Jin, S; Li, S; Tong, Q; Wang, Y	1
Beukema, JC; Biermann, K; Blaisse, RJ; Bonenkamp, JJ; Busch, OR; Creemers, GJ; Cuesta, MA; Hospers, GA; Hulshof, MC; Nieuwenhuijzen, GA; Piet, AH; Plukker, JT; Punt, CJ; Reinders, JG; Richel, DJ; Rozema, T; Spillenaar Bilgen, EJ; Steyerberg, EW; ten Kate, FJ; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van der Sangen, MJ; van Hagen, P; van Lanschot, JJ; van Rij, CM; Verheul, HM; Wijnhoven, BP	1
Gong, Y; Huang, M; Li, N; Liu, Y; Peng, F; Wang, J; Xu, Y; Zhang, J; Zhou, L; Zhu, J	1
Bu, S; Chen, Y; Guo, W; He, C; Liu, J; Tan, B; Wang, J; Wang, W; Wang, Y; Wu, X	1
Chang, AC; Hayman, JA; Lee, JS; Merajver, SD; Orringer, MB; Pan, CC; Pickens, A; Schneider, BJ; Urba, SG	1
Hu, X; Huang, W; Jing, X; Liu, L; Liu, S; Tong, T; Wang, R; Wu, W; Yue, J; Zheng, Y	1
Bergman, JJ; Blom, RL; Busch, OR; Hulshof, MC; Klinkenbijl, JH; Reitsma, JB; Richel, DJ; van Berge Henegouwen, MI; van Heijl, M; Wilmink, JW	1
Chen, EC; Chen, XM; Hao, CG; Ma, JB; Qin, G; Song, YP; Wei, L	1
Du, XH; Mao, WM; Wang, SY; Xu, YP; Zhang, SZ	1
Huang, Z; Ma, L; Ou, Y; Song, Y; Yu, C; Zhan, Q; Zhang, B; Zhao, C; Zhou, W	1
Cai, Y; Hu, M; Jiang, F; Liu, C; Liu, Q; Luo, J; Luo, M; Shi, Q; Song, P; Tang, M; Weng, Y; Yang, D; Zhan, X; Zhang, F; Zhang, Y; Zhou, L; Zuo, G	1
Liu, F; Sun, YL; Wang, LS; Xu, Y; Zhao, XH	1
He, J; Huang, J; Mao, Y; Qu, T; Quan, L; Sun, Y; Wang, J; Xing, P; Xu, N; Zhang, H; Zhou, Y; Zhu, H	1
Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D	1
Adenis, A; Mariette, C; Mirabel, X	1
Cheng, HY; Gu, M; Huang, XE; Li, SY; Lin, Y; Liu, L	1
Ajani, JA	2
Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; Van der Gaast, A; Verweij, J	1
Bains, MS; Ginsberg, R; Ilson, DH; Kelsen, DP; Korst, R; Minsky, B; Rusch, V; Stojadinovic, A; Turnbull, A	1
Barón, MG; Belda-Iniesta, C; Casado, E; Castelo, B; Corral de la Calle, M	1
Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F	1
Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT	1
Aston, D; Brewster, AE; Crosby, TD; Minett, M; Mukherjee, S	1
Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V	1
Eskens, FA; Hoekstra, R; Polee, MB; Siersema, PD; Stoter, G; Tilanus, HW; Van der Burg, ME; Van der Gaast, A	1
Ajani, JA; Correa, AM; Cox, JD; Komaki, R; Lahoti, S; Martin, F; Nesbitt, JC; Putnam, JB; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL	1
Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C	1
Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T	1
Anderson, SE; Ilson, DH; Kelsen, DP; O'Reilly, EM	1
O'Neil, BH; Socinski, MA	1
Beard, M; Coia, L; Colarusso, P; Farma, J; Frucht, H; Goldberg, M; Goosenberg, E; Lampert, C; Weiner, LM	1
Benson, AB; Blanke, CD; Hecht, JR; Lenz, HJ	1
Ajani, JA; Faust, J; Komaki, R; Putnam, JB; Rice, D; Roth, J; Smythe, R; Stevens, C; Swisher, S; Vaporciyan, A; Walsh, G; Yao, J	1
Hayman, JA; Ianettonni, M; Orringer, MB; Satoru, H; Urba, SG	1
Anderson, SE; Bains, M; Ilson, DH; Kelsen, DP; Minsky, BD	1
Altorki, NK; Keresztes, RS; Korst, RJ; Pasmantier, MW; Port, JL	1
Bains, MS; Brenner, B; Gonen, M; Ilson, DH; Kelsen, DP; Minsky, BD; Tong, W	1
Constantinou, M; Safran, H; Tsai, JY	1
Chen, GA; Cole, G; Nguyen, DM; Reddy, R; Schrump, DS; Schrump, WD; Tsai, W	1
Eskens, FA; Hoekstra, R; Polee, MB; Sparreboom, A; Stoter, G; van de Schaaf, J; van der Gaast, A; Verweij, J	1
El-Rayes, BF; Ferris, A; Heilbrun, LK; Jain, V; Philip, PA; Shields, A; Terry, D; Zalupski, M	1
Ajani, JA; Cohen, DS; Faust, J; Komaki, R; Lynch, PM; Morris, J; Nivers, R; Putnam, JB; Roth, JA; Smythe, R; Swisher, SG; Vaporciyan, A; Walsh, G; Wu, TT	1
Buck, DA; Chung, TD; Fréchette, E; Kachnic, LA; Kaplan, BJ; Neifeld, JP; Shaw, JE	1
Ancukiewicz, M; Choi, N; Donahue, D; Lynch, T; Mathisen, D; Park, SD; Wain, J; Wright, C	1
Beller, E; Bessell, JR; Burmeister, BH; Burmeister, E; Doyle, L; Gotley, DC; Harvey, JA; Martin, I; Smithers, BM; Thomas, J; Thomson, DB; Walpole, ET	1
Ajani, J; Allen, P; Chang, JY; Cox, JD; Guerrero, T; Jeter, M; Jin, J; Komaki, R; Liao, Z; Putnam, J; Roth, J; Smythe, R; Stevens, CW; Swisher, S; Vaporciyan, A; Walsh, G; Yao, J; Zhang, Z	1
Li, X; Song, HY; Yang, YM; Zhang, SL	1
Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT	1
Armanios, M; Benson, AB; Forastiere, AA; Haller, DG; Kugler, JW; Xu, R	1
Adrian, A; Chak, B; Choy, H; Cioffi, W; DiPetrillo, T; Goldstein, L; Hughes, M; Kennedy, T; Maia, C; Nadeem, A; Ng, T; Pasquariello, T; Pepperell, JR; Rathore, R; Reeder, L; Safran, H; Steinhoff, M; Tantravahi, U; Tsai, JY; Wanebo, H	1
Aujeský, R; Benes, P; Hajdúch, M; Havlík, R; Klein, J; Král, V; Neoral, C; Vrba, R	1
Hennequin, C	1
Ajani, JA; Crane, CH; Faust, J; Feig, B; Janjan, N; Lunagomez, S; Lynch, PM; Mansfield, PF; Morris, J; Nivers, R; Pisters, PW; Wu, TT; Yao, JC	1
Bader, SB; Louie, J; Molendyk, J; Phillips, M; Regan, J; Ross, HJ; Ruzich, J; Seligman, M; Seung, SK; Skokan, L; Smith, JW; Soo, E	1
Cai, RG; Chu, DT; Cui, CX; Huang, J; Meng, PJ; Sun, Y; Wang, JW; Yang, L; Zhang, MJ	1
Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T	1
Hada, T; Hara, T; Hirano, M; Hirano, Y; Kikkawa, H; Nakada, K; Nozawa, H; Oyama, K; Takagi, T	1
Faried, A; Faried, LS; Kanuma, T; Kato, H; Kimura, H; Kuwano, H; Miyazaki, T; Nakajima, M; Sohda, M	1
Byun, JR; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Na, KJ; Song, SY; Yang, DH	1
Becker, K; Bekesch, M; Busch, R; Ewald, P; Feith, M; Höfler, H; Langer, R; Sarbia, M; Siewert, JR; Specht, K; Stein, HJ	1
Bosset, JF; Bosset, M; Buffet, J; Chaigneau, L; Créhange, G; Lorchel, F; Mantion, G; Servagi, S	1
Nguyen, DM; Schrump, DS	1
Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Inui, T; Kamata, M; Matsuoka, M; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yasui, H; Yoshino, T; Zenda, S	1
Beard, M; Cheng, JD; Freedman, G; Goldberg, M; Henry, LR; Konski, A; McLaughlin, S; Meropol, NJ; Scott, W; Watts, P; Weiner, LM	1
Fujita, F; Fujita, M; Shakuto, S	1
Li, SY; Liu, L; Sun, XC	1
Colville, JA; Ginsberg, MS; Hricak, H; Ilson, D; Kalaigian, J; Mazumdar, M; Schwartz, GK; Schwartz, LH; Wang, L	1
Eijkenboom, WM; Muller, K; Siersema, PD; Tilanus, HW; Tran, TC; van Dekken, H; van der Gaast, A; van Meerten, E	1
Ajani, JA; Bleyer, A; Chang, BB; Cherny, RC; Craig, C; Dakhil, S; Faust, J; Ho, L; Jiang, Y; Rousey, S; Yao, JC	1
Abraham, J; Askill, C; Brewster, A; Court, J; Crosby, T; Hardwick, R; Havard, T; Lewis, W; Manson, J; Mukherjee, S; Roberts, SA; Williamst, GT	1
Choi, NC; Coen, J; Fidias, P; Lynch, TJ; Roof, KS; Willett, CG; Wright, C	1
Minsky, BD	1
Boellaard, R; Crezee, H; Hoekstra, OS; Hulshof, MC; Omloo, JM; Sloof, GW; ten Kate, FJ; van Lanschot, JJ; Vervenne, WL; Westerterp, M	1
Abbrederis, K; Bassermann, F; Busch, R; Lordick, F; Peschel, C; Roethling, N; Schuhmacher, C; Sendler, A; Siewert, JR; Voelter, V	1
Chiba, N; Hanada, M; Ishioka, C; Kakudo, Y; Kato, S; Noguchi, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Shimodaira, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T	1
Akerman, P; Chauhan, B; Cruff, D; Dipetrillo, T; Evans, D; Harrington, D; Iannitti, D; Milas, L; Miner, T; Ng, T; Safran, H	1
Becker, K; Busch, R; Ewald, P; Feith, M; Höfler, H; Langer, R; Sarbia, M; Siewert, JR; Specht, K; Stein, HJ	1
Ajani, J; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Wang, SL	1
Akerman, P; Benton, D; Dipetrillo, T; Evans, D; Goldstein, L; Kennedy, T; Ng, T; Purviance, J; Safran, H; Steinhoff, M; Tantravahi, U	1
Beauchamp, RD; Berlin, J; Blanke, CD; Chakravarthy, B; Kim, DW; Shyr, Y; Wu, H	1
Ahmad, SA; Firdaus, I; Howington, JA; James, L; Jazieh, AR; Lowy, AM; Redmond, K; Reed, MF; Rose, P; Roychowdhury, D; Safa, M; Sussman, JJ	1
Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D	1
Ilson, DH; Kelsen, DP; Leichman, LP; Wadleigh, RG	1
Bold, RJ; Follette, D; Gandara, D; Goldberg, Z; Lau, D; Narayan, S; Ryu, J; Tanaka, M; Urayama, S; Wang, H	1
Eatock, MM; Eskens, FA; Evans, TR; Ferry, DR; Hawkins, RE; Jones, RJ; Wilke, H	1
Chen, A; Ding, F; Liu, Z; Luo, A; Ren, S; Yu, Z; Zhang, L; Zhang, S	1
Ardalan, B; Avisar, E; Bowen-Wells, CP; Franceschi, D; Ganjei-Azar, P; Lima, M; Livingstone, AS; Mezentsev, D; Rios, J; Sapp, M; Sparling, L; Spector, SA; Walker, G	1
Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH	1
Bendell, JC; Cohen, DP; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Lockhart, AC; Petros, WP; Truax, R; Willett, CG	1
Bendell, JC; Chino, JP; Clough, RW; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG	1
Creemers, GJ; Nieuwenhuijzen, GA; Romme, EA; Rutten, HJ; van de Schoot, L; van der Sangen, MJ; van Driel, OJ; van Lijnschoten, G	1
Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Lair, BS; Martenson, JA; McLeod, HL; Moore, DF; Nichols, F; Tschetter, LK	1
Morita, R; Nishikawa, M; Okuda, T; Sakata, C; Tokuhara, T	1
Jin, ML; Li, J; Li, Y; Shen, L; Zhang, XD; Zhang, XT	1
Akerman, P; Dipetrillo, T; Doyle, LA; Evans, D; Kennedy, N; Kennedy, T; Krasna, M; Ng, T; Plette, A; Safran, H; Spector, J; Suntharalingam, M; Wanebo, H	1
Hosono, Y; Maruyama, K; Motoyama, S; Okuyama, M; Saito, R	1
Essink-Bot, ML; Looman, CW; Muller, K; Tilanus, HW; van der Gaast, A; van Meerten, E	1
Capanu, M; Ilson, DH; Kelsen, DP; Ku, GY; O'Reilly, E; Schwartz, GK; Schwartz, LH; Shah, MA	1
Ajani, JA; Cox, JD; Hu, C; Komaki, R; Liao, Z; Liu, HH; Mohan, R; Phan, A; Swisher, SG; Tucker, SL; Wang, S; Wei, X	1
Jin, M; Li, J; Li, Y; Shen, L; Zhang, X	1
Wu, SX; Xie, CY; Zhang, P	1
Ross, HJ; Seung, SK; Smith, JW	1
Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP	1
Dees, EC; Goldberg, RM; Hayes, DN; Lee, CB; Moore, DT; Socinski, MA; Stinchcombe, TE	1
Chang, YL; Cheng, JC; Hsu, CH; Hsu, FM; Lee, JM; Lee, YC; Lin, CC; Tsai, YC	1
Belani, CP; Christie, NA; Cooper, K; Gibson, MK; Land, SR; Landreneau, RJ; Luketich, JD; Pennathur, A; Schuchert, M; Ward, J	1
Ajani, J; Daugherty, K; Ilson, D; Kelsen, D; Pazdur, R	1
Ajani, JA; Daugherty, K; Ilson, DH; Kelsen, DP	1
Ajani, JA; Daugherty, K; Ilson, DH; Kelsen, DP; Lynch, PM; Pazdur, R	1
Aiba, K; Akatsuka, Y; Besho, A; Horikoshi, N; Inamoto, Y; Inoue, K; Mukaiyama, T; Ogihara, A; Sumida, T; Uchida, T	1
Arbuck, SG	1
Ilson, DH; Kelsen, DP	1
Ajani, JA; Ilson, DH; Kelsen, DP	1
Benson, AB; Einzig, AI; Karp, DD; Neuberg, D; O'Dwyer, PJ; Remick, SC; Stewart, JA	1
Aisner, J; Cortés-Funes, H	1
Furuhata, T; Hirata, K; Kimura, Y; Nakamura, Y; Nishimori, H; Shiratsuchi, T; Tokino, T	1
Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD	1
Rowinsky, EK	1
Greco, FA; Hainsworth, JD; Meluch, AA	1
Arquette, M; Bains, M; Cooper, J; Forastiere, AA; Ginsberg, R; Ilson, D; Kelsen, D	1
Kerkhofs, L; Kok, TC; Splinter, TA; van der Gaast, A; Vos, R	1
Gadgeel, S; Hussain, M; Philip, PA; Shields, A; Zalupski, MM	1
Belani, CP; Day, R; Ferson, PF; Keenan, RJ; Kim, R; Landreaneau, RJ; Lembersky, B; Luketich, JD; Posner, M; Ramanathan, RK; Seeger, J	1
Coia, LR; Colarusso, P; Dresler, C; Goldberg, M; Weiner, LM	1
Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE; Watson, SM	1
Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C	1
Haraf, DJ; Hoffman, PC; Mauer, AM; Vokes, EE	1
Graeven, U; König, M; Petrasch, S; Reinacher, A; Schmiegel, W; Welt, A	1
Weiner, LM	1
Beauchamp, RD; Blanke, CD; Choy, H; Johnson, DH; Leach, S; Roberts, J; Teng, M; Washington, K	1
Akerman, P; Cioffi, W; Gaissert, H; Hesketh, PJ; Joseph, P; King, T; Safran, H; Wanebo, H	1
Anderson, NR; Bern, MM; Coco, FV; Dow, E; Lokich, JJ; Oliynyk, P; Sonneborn, H	1
Kerkhofs, L; Kok, TC; Siersema, PD; Splinter, TA; Tilanus, HW; van der Gaast, A	1
Choy, H	1
Wright, CD	1
Burtness, BA; Canto, MI; Forastiere, AA; Heath, EI; Heitmiller, RF; Kaufman, HS; Kleinberg, L; Knisely, JP; Olukayode, K; Salem, R; Talamini, MA; Topazian, M; Wu, TT; Yang, SC	1
Adelstein, DJ; Ciezki, J; DeCamp, M; Dumot, JA; Larto, MA; Rice, TW; Rybicki, LA; Saxton, J; Vargo, JJ; Zuccaro, G	1
Chen, KT	1
Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD	1
D'Amico, TA; Harpole, DH	1
Edelman, MJ	1
Enzinger, PC; Ilson, DH	1
Ajani, JA; Komaki, R; Pisters, PW; Putnam, J; Roth, JA; Schnirer, II; Swisher, S; Yao, JC	1
Piedbois, Y; Thirion, P	1
Akerman, P; Chen, MH; Gaissert, H; Graziano, S; Hesketh, PJ; Koness, J; Moore, T; Safran, H; Wanebo, HJ	1
Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E	1
Ajani, JA; Komaki, R; Lahoti, S; Lynch, PM; Martin, FD; Nesbitt, J; Pisters, PW; Putnam, JB; Raijman, I; Roth, JA; Smythe, R; Swisher, S; Vaporciyan, A; Walsh, G	1
Law, S; Wong, J	1
Eskens, FA; Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; van der Burg, ME; van der Gaast, A; Verweij, J	1
Ilson, DH	1
Guillet, G; Karam, A; Labat, JP; Leroy, JP; Metges, JP	1
Ando, N; Shih, CH	1
Forastiere, AA; Heath, EI; Marshall, J; Piantadosi, S; Urba, S	1

Reviews

40 review(s) available for paclitaxel and Cancer of Esophagus

Article	Year
Molecular mechanisms associated with chemoresistance in esophageal cancer. Cellular and molecular life sciences : CMLS, 2022, Feb-03, Volume: 79, Issue:2 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Esophageal Neoplasms; Fluorouracil; Humans; Molecular Targeted Therapy; Mutation; Paclitaxel; Tumor Microenvironment	2022
[News in gastrointestinal radiotherapy: The esophageal cancer]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2022, Volume: 26, Issue:6-7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Humans; Lung Neoplasms; Nivolumab; Paclitaxel; Trastuzumab	2022
Approach to Localized Squamous Cell Cancer of the Esophagus. Current treatment options in oncology, 2022, Volume: 23, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Platinum; Quality of Life	2022
Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. Frontiers in immunology, 2022, Volume: 13 Topics: B7-H1 Antigen; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Paclitaxel	2022
Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3. Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2 Topics: Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Paclitaxel; Retrospective Studies; Taxoids	2023
Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01). Future oncology (London, England), 2023, Volume: 19, Issue:34 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic	2023
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer. Expert opinion on biological therapy, 2019, Volume: 19, Issue:11 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Humans; Paclitaxel; Ramucirumab; Stomach Neoplasms; Vascular Endothelial Growth Factor A	2019
Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clinical oncology (Royal College of Radiologists (Great Britain)), 2020, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies	2020
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. The Cochrane database of systematic reviews, 2020, 11-19, Volume: 11 Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunotherapy; Irinotecan; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Stomach Neoplasms	2020
Fluoroscopy-Guided Salvage Photodynamic Therapy Combined with Nanoparticle Albumin-Bound Paclitaxel for Locally Advanced Esophageal Cancer after Chemoradiotherapy: A Case Report and Literature Review. Cancer biotherapy & radiopharmaceuticals, 2022, Volume: 37, Issue:5 Topics: Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluoroscopy; Humans; Male; Malnutrition; Nanoparticles; Paclitaxel; Photochemotherapy; Quality of Life; Salvage Therapy	2022
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2017, Volume: 35, Issue:12 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Ramucirumab; Stomach Neoplasms; Taxoids; Technology Assessment, Biomedical	2017
A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival. Critical reviews in oncology/hematology, 2018, Volume: 127 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Network Meta-Analysis; Paclitaxel; Survival Analysis	2018
Endoscopy innovations. Endoscopy, 2014, Volume: 46, Issue:9 Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug-Eluting Stents; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophageal Sphincter, Lower; Humans; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Pancreatic Neoplasms; Portal Vein; Suture Techniques; Tomography, Optical Coherence	2014
[Adjuvant treatment for esophagogastric junction cancer]. Nihon Geka Gakkai zasshi, 2015, Volume: 116, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur	2015
Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:11 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum Compounds; Randomized Controlled Trials as Topic; Treatment Outcome	2015
Ramucirumab: A Review in Advanced Gastric Cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2015, Volume: 29, Issue:5 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Humans; Hypertension; Paclitaxel; Ramucirumab; Stomach Neoplasms	2015
The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma. Expert review of anticancer therapy, 2016, Volume: 16, Issue:10 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Humans; Paclitaxel; Ramucirumab; Stomach Neoplasms; Survival Rate; Vascular Endothelial Growth Factor Receptor-2	2016
Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer. Cancer letters, 2017, 08-01, Volume: 400 Topics: Administration, Metronomic; Antineoplastic Agents; Capecitabine; Cyclophosphamide; Esophageal Neoplasms; Evidence-Based Medicine; Humans; Paclitaxel; Patient Selection; Stomach Neoplasms; Treatment Outcome	2017
Docetaxel for gastric and esophageal carcinomas. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:6 Suppl 6 Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Clinical Trials as Topic; Docetaxel; Esophageal Neoplasms; Humans; Paclitaxel; Stomach Neoplasms; Taxoids	2002
Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer investigation, 2003, Volume: 21, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Humans; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2003
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. The Annals of thoracic surgery, 2004, Volume: 78, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2004
[Association of taxanes and radiotherapy: preclinical and clinical studies]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1 Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured	2004
Radiation and chemoradiation therapy for esophageal adenocarcinoma. Journal of surgical oncology, 2005, Dec-01, Volume: 92, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Humans; Paclitaxel; Radiotherapy Dosage; Randomized Controlled Trials as Topic	2005
Novel molecular targeted therapy for esophageal cancer. Journal of surgical oncology, 2005, Dec-01, Volume: 92, Issue:3 Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Transformation, Neoplastic; Clinical Trials as Topic; Depsipeptides; DNA Methylation; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glycoproteins; Histone Deacetylase Inhibitors; Humans; Mitogen-Activated Protein Kinases; Paclitaxel; Protein Kinase C; Signal Transduction	2005
[Progress of medical and combined treatment for esophageal carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Vinblastine; Vinorelbine	2006
Primary combined-modality therapy for esophageal cancer. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:5 Topics: Algorithms; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome	2006
Management of esophageal cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:9 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Premedication; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine	1996
Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Paclitaxel; Urinary Bladder Neoplasms	1997
Paclitaxel pharmacology and other tumor types. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Endometrial Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphoma; Male; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Platinum Compounds; Sarcoma, Kaposi; Stomach Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine	1997
Treatment of patients with upper gastrointestinal carcinomas. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Therapy, Combination; Esophageal Neoplasms; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Stomach Neoplasms	1997
Paclitaxel in the treatment of esophageal cancer. Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 2 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Humans; Neoplasm Metastasis; Paclitaxel	1999
Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate	1999
Taxanes in combined-modality therapy for solid tumors. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids	1999
Molecular biology of esophageal cancer. Chest surgery clinics of North America, 2000, Volume: 10, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Barrett Esophagus; Biomarkers, Tumor; Carcinoma, Squamous Cell; DNA Damage; Esophageal Neoplasms; Genes, p53; Humans; Incidence; Mutation; Paclitaxel; Prognosis; Risk Factors	2000
Recent developments in the chemotherapy of advanced esophageal cancer. Chest surgery clinics of North America, 2000, Volume: 10, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel	2000
Irinotecan in esophageal cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Paclitaxel; Topoisomerase I Inhibitors	2000
New adjuvant therapies for esophageal cancer. Advances in surgery, 2001, Volume: 35 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Taxoids	2001
New developments in the treatment of esophageal cancer. Current oncology reports, 2002, Volume: 4, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Humans; Irinotecan; Paclitaxel; Survival Rate	2002
[Chemotherapy for the patients with esophageal cancer]. Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel	2002

Trials

188 trial(s) available for paclitaxel and Cancer of Esophagus

Article	Year
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 2021, 09-14, Volume: 326, Issue:10 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immunotherapy; Male; Middle Aged; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Survival Analysis	2021
Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancer biotherapy & radiopharmaceuticals, 2022, Volume: 37, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Paclitaxel; Pyridines	2022
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. The lancet. Gastroenterology & hepatology, 2021, Volume: 6, Issue:12 Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; China; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Malaysia; Male; Middle Aged; Paclitaxel; Philippines; Placebos; Progression-Free Survival; Ramucirumab; Safety; Stomach Neoplasms; Thailand; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2	2021
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-01, Volume: 40, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome	2022
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer, 2022, 03-01, Volume: 128, Issue:5 Topics: Antibodies, Monoclonal, Humanized; China; Esophageal Neoplasms; Esophagogastric Junction; Humans; Paclitaxel; Stomach Neoplasms	2022
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study. Frontiers in immunology, 2021, Volume: 12 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immunotherapy; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome	2021
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab	2022
Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Piperidines; Progression-Free Survival; Ramucirumab; Stomach Neoplasms	2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nature communications, 2022, 02-14, Volume: 13, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immune Checkpoint Inhibitors; Irinotecan; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Receptors, Antigen, T-Cell	2022
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. JAMA network open, 2022, 02-01, Volume: 5, Issue:2 Topics: Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Paclitaxel	2022
Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial. Radiation oncology (London, England), 2022, Jun-09, Volume: 17, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel	2022
Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer. Radiation oncology (London, England), 2022, Sep-14, Volume: 17, Issue:1 Topics: Carboplatin; Chemoradiotherapy; Deglutition Disorders; Esophageal Neoplasms; Humans; Paclitaxel; Palliative Care; Stomach Neoplasms	2022
Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial. Frontiers in immunology, 2022, Volume: 13 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Paclitaxel; Prospective Studies	2022
High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial. International journal of radiation oncology, biology, physics, 2023, 04-01, Volume: 115, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nutrition Assessment; Nutritional Status; Paclitaxel; Radiotherapy, Intensity-Modulated	2023
Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9). Radiation oncology (London, England), 2023, Feb-07, Volume: 18, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel	2023
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. EBioMedicine, 2023, Volume: 90 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Deglutition Disorders; Ecosystem; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Multiomics; Neoadjuvant Therapy; Paclitaxel	2023
The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma. Thoracic cancer, 2023, Volume: 14, Issue:15 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Retrospective Studies	2023
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09). Targeted oncology, 2023, Volume: 18, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Eye Proteins; Homeodomain Proteins; Humans; Paclitaxel; Ramucirumab; Stomach Neoplasms; Transcription Factors; Treatment Outcome	2023
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. The oncologist, 2023, 09-07, Volume: 28, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Humans; Paclitaxel; Stomach Neoplasms	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Sexuality research & social policy : journal of NSRC : SR & SP, 2023, Apr-05 Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bioaccumulation; Blood Glucose; Brain; Brassica napus; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Catalysis; Child; China; Chlorides; Chlorine; Chromium; Chronic Disease; Cohort Studies; Copper; Corrosion; COVID-19; Creatinine; Dermatitis; Diabetes Mellitus; Diazepam; Disease-Free Survival; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Dyspnea; Electron Spin Resonance Spectroscopy; Environmental Monitoring; Escherichia coli; Escherichia coli Infections; Esophageal Neoplasms; Esophagogastric Junction; Estradiol; Exercise Test; Exercise Tolerance; Female; Ferric Compounds; Fishes; Food Chain; gamma-Aminobutyric Acid; Genomics; Halogenation; HEK293 Cells; Hemolysis; Heterocyclic Compounds; Hospitalization; Humans; Hydrogen Peroxide; Hyperglycemia; Introns; Iron; Kidney; Kinetics; Laboratories; Limit of Detection; Lipopolysaccharides; Liver Neoplasms; Magnesium; Male; Mammals; Materials Testing; Mercury; Metal-Organic Frameworks; Methylmercury Compounds; Mice; Microscopy, Electron, Scanning; Mifepristone; Minerals; Molecular Weight; Mutation; Nanoparticles; Neuroprotection; NF-kappa B; Nitrates; Nitrogen; NLR Family, Pyrin Domain-Containing 3 Protein; Orthopedics; Ovarian Neoplasms; Ovariectomy; Oxidation-Reduction; Oxidative Stress; Oxygen; Oxygen Consumption; Paclitaxel; Phenols; Progesterone; Prospective Studies; Proteins; Protons; Pulmonary Disease, Chronic Obstructive; Ramucirumab; Rats; Receptor, ErbB-2; Respiratory Function Tests; Retrospective Studies; Saliva; SARS-CoV-2; Seeds; Sesbania; Shock, Septic; Silicon Dioxide; Sleep; Soil; Specimen Handling; Spectroscopy, Mossbauer; Spin Labels; Staphylococcus aureus; Stomach Neoplasms; Streptococcus mutans; Thiamine; Toll-Like Receptor 2; Toll-Like Receptor 4; Trastuzumab; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Water; Water Pollutants, Chemical; Water Purification; Xeroderma Pigmentosum; Zebrafish	2023
A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer. Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Survival Rate	2019
Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas. International journal of radiation oncology, biology, physics, 2020, 02-01, Volume: 106, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Chemoradiotherapy; Dose Fractionation, Radiation; Esophageal Fistula; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagitis; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Re-Irradiation; Tumor Burden	2020
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 02-10, Volume: 38, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cardiotoxicity; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Humans; Male; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab	2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; France; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate	2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. European journal of cancer (Oxford, England : 1990), 2020, Volume: 127 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Follow-Up Studies; Humans; Paclitaxel; Prognosis; Ramucirumab; Stomach Neoplasms; Vascular Endothelial Growth Factor D	2020
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 06-10, Volume: 38, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab	2020
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. The New England journal of medicine, 2020, 06-18, Volume: 382, Issue:25 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Marrow; Camptothecin; Esophageal Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab	2020
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial. British journal of cancer, 2020, Volume: 123, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel	2020
A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC cancer, 2020, Sep-22, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated	2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 12-10, Volume: 38, Issue:35 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Survival Rate; Young Adult	2020
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial. International journal of radiation oncology, biology, physics, 2021, 08-01, Volume: 110, Issue:5 Topics: Aged; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiotherapy, Intensity-Modulated; Time Factors; Treatment Failure	2021
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA surgery, 2021, 05-01, Volume: 156, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Intention to Treat Analysis; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Postoperative Complications; Prospective Studies; Quality of Life; Survival Rate; Thoracoscopy	2021
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 06-20, Volume: 39, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Treatment Outcome	2021
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:9 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Esophageal Neoplasms; Humans; Paclitaxel	2021
Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 09-01, Volume: 39, Issue:25 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate	2021
Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:1 Topics: Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Induction Chemotherapy; Paclitaxel; Treatment Outcome	2022
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma. Oncotarget, 2017, Jun-06, Volume: 8, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Paclitaxel; Remission Induction; Retrospective Studies; Tegafur; Vomiting	2017
ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC cancer, 2017, 06-03, Volume: 17, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life	2017
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA oncology, 2017, Nov-01, Volume: 3, Issue:11 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Time Factors; Treatment Outcome	2017
Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE). BMC cancer, 2017, Jul-13, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Female; Geriatric Assessment; Humans; Male; Paclitaxel; Prospective Studies; Quality of Life	2017
Phase II study of concurrent chemoradiotherapy with a modified target volumes delineation method for inoperable oesophagealcancer patients. The British journal of radiology, 2017, Volume: 90, Issue:1077 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Survival Rate	2017
Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 02-01, Volume: 29, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Digestive System Surgical Procedures; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quality of Life; Surveys and Questionnaires	2018
Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 01-20, Volume: 36, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Health Status; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quality of Life; Radiotherapy Dosage; Surveys and Questionnaires; Time Factors; Treatment Outcome	2018
A clinical trial protocol paper discussing the BRIGHTER study. Future oncology (London, England), 2018, Volume: 14, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Clinical Protocols; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Esophageal Neoplasms; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Naphthoquinones; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2018
Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. Lancet (London, England), 2018, 07-14, Volume: 392, Issue:10142 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Immunotherapy; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Treatment Outcome	2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet (London, England), 2018, 07-14, Volume: 392, Issue:10142 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome	2018
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Signet Ring Cell; Choice Behavior; Decision Support Techniques; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Stomach Neoplasms; Survival Rate; Young Adult	2018
[Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2018, Sep-25, Volume: 21, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Esophagogastric Junction; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Survival Rate	2018
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). BMJ open, 2018, 10-21, Volume: 8, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; China; Cisplatin; Clinical Trials as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2018
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Retrospective Studies; Survival Analysis; Taiwan; Treatment Outcome	2019
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Investigational new drugs, 2019, Volume: 37, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate	2019
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. American journal of clinical oncology, 2019, Volume: 42, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Prognosis; Prospective Studies	2019
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 07-10, Volume: 37, Issue:20 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Photons; Proportional Hazards Models; Treatment Outcome; Young Adult	2019
Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer. The British journal of surgery, 2019, Volume: 106, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbon Monoxide; Carboplatin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postoperative Complications; Preoperative Care; Quality of Life; Respiration Disorders; Vital Capacity	2019
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Annals of surgical oncology, 2013, Volume: 20, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Survival Rate	2013
A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World journal of gastroenterology, 2013, Sep-21, Volume: 19, Issue:35 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Time Factors; Treatment Outcome	2013
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Risk Factors; Stomach Neoplasms; Time Factors; Treatment Outcome	2014
A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma. American journal of clinical oncology, 2016, Volume: 39, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate	2016
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Cohort Studies; Drug Monitoring; Epirubicin; Esophageal Neoplasms; Esophagus; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pilot Projects; Severity of Illness Index; Stomach; Stomach Neoplasms; Survival Analysis	2014
Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study. International journal of radiation oncology, biology, physics, 2014, Sep-01, Volume: 90, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Esophageal Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Panitumumab; Preoperative Care	2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Ramucirumab; Remission Induction; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2014
Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. Internal medicine journal, 2015, Volume: 45, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cyclobutanes; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel	2015
FDA Approval Summary: Ramucirumab for Gastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Aug-01, Volume: 21, Issue:15 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Ramucirumab; Stomach Neoplasms	2015
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Paclitaxel	2015
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis	2015
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Asian People; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Ramucirumab; Stomach Neoplasms; Survival Rate; Treatment Outcome	2016
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5 Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult	2015
The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel	2016
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. BMC cancer, 2015, Oct-14, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Retreatment; Treatment Outcome	2015
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Quality of Life; Ramucirumab; Treatment Outcome	2016
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. Cancer science, 2016, Volume: 107, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel	2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast cancer research and treatment, 2016, Volume: 155, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Esophageal Neoplasms; Female; Heterocyclic Compounds, 3-Ring; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome	2016
The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome	2016
Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcom International journal of radiation oncology, biology, physics, 2016, Mar-15, Volume: 94, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage; Survival Rate	2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. American journal of clinical oncology, 2017, Volume: 40, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Piperidines; Quinazolines; Treatment Outcome	2017
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. BMC cancer, 2016, 05-18, Volume: 16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome; Young Adult	2016
Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget, 2016, Aug-02, Volume: 7, Issue:31 Topics: Aged; Albumins; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Prognosis; Treatment Outcome	2016
Activities of daily living and quality of life during treatment with neoadjuvant chemoradiotherapy and after surgery in patients with esophageal cancer. Journal of surgical oncology, 2016, Volume: 114, Issue:6 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cross-Sectional Studies; Disability Evaluation; Esophageal Neoplasms; Esophagectomy; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Quality of Life; Treatment Outcome	2016
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma. Oncotarget, 2016, Aug-30, Volume: 7, Issue:35 Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Paclitaxel; Treatment Outcome; Vascular Endothelial Growth Factor A	2016
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer. Medical science monitor : international medical journal of experimental and clinical research, 2017, Jan-24, Volume: 23 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Retrospective Studies	2017
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Rate; Treatment Outcome	2008
Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie, 2008, Volume: 31, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome	2008
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC surgery, 2008, Nov-26, Volume: 8 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Patient Selection; Quality of Life; Radiotherapy Dosage; Research Design	2008
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome	2009
Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anti-cancer drugs, 2009, Volume: 20, Issue:2 Topics: Aged; Combined Modality Therapy; Deglutition Disorders; Delayed-Action Preparations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	2009
Neoadjuvant radiochemotherapy increases matrix metalloproteinase activity in healthy tissue in esophageal cancer patients. Annals of surgical oncology, 2009, Volume: 16, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagus; Female; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant	2009
Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer. Japanese journal of clinical oncology, 2009, Volume: 39, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome	2009
A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer. Japanese journal of clinical oncology, 2009, Volume: 39, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome	2009
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2010, Volume: 23, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Longitudinal Studies; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Thrombocytopenia; Treatment Outcome	2010
Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. International journal of radiation oncology, biology, physics, 2010, Dec-01, Volume: 78, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Feasibility Studies; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Thrombocytopenia	2010
A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome	2010
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. British journal of cancer, 2010, Apr-27, Volume: 102, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Life Expectancy; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Patient Selection; Stilbenes	2010
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer investigation, 2010, Volume: 28, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Platelet Count; Prognosis; Radiotherapy; Survival Rate; Time Factors	2010
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds	2011
[A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Survival Rate	2010
[A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer]. Zhonghua yi xue za zhi, 2010, Jul-27, Volume: 90, Issue:28 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Infusion Pumps; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel	2010
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Annals of surgery, 2011, Volume: 253, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; ROC Curve; Treatment Outcome	2011
Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. American journal of clinical oncology, 2012, Volume: 35, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagitis; Esophagogastric Junction; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Paclitaxel; Polyglutamic Acid; Treatment Outcome	2012
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. International journal of radiation oncology, biology, physics, 2012, Apr-01, Volume: 82, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Radiotherapy Dosage; Salvage Therapy; Survival Rate	2012
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC cancer, 2011, Sep-02, Volume: 11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel	2011
Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Indoles; Male; Middle Aged; Paclitaxel; Pyrroles; Sunitinib	2012
Preoperative chemoradiotherapy for esophageal or junctional cancer. The New England journal of medicine, 2012, May-31, Volume: 366, Issue:22 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care	2012
Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer science, 2012, Volume: 103, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	2012
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer. Investigational new drugs, 2013, Volume: 31, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Molybdenum; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Preoperative Care; Prognosis; Remission Induction; Survival Rate	2013
A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2013
A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult	2012
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Analysis; Treatment Outcome	2002
A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. The Journal of thoracic and cardiovascular surgery, 2002, Volume: 124, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Diagnostic Imaging; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	2002
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2003
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. International journal of gastrointestinal cancer, 2002, Volume: 32, Issue:2-3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting	2002
Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Survival Analysis; Treatment Outcome	2003
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. International journal of radiation oncology, biology, physics, 2003, Sep-01, Volume: 57, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Longitudinal Studies; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome	2003
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. British journal of cancer, 2003, Aug-18, Volume: 89, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2003
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer investigation, 2003, Volume: 21, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Treatment Outcome	2003
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report. The Journal of thoracic and cardiovascular surgery, 2003, Volume: 126, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Preoperative Care; Survival Rate	2003
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant	2003
Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer, 2003, Nov-15, Volume: 98, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis	2003
Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. The Journal of thoracic and cardiovascular surgery, 2003, Volume: 126, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Preoperative Care; Risk Assessment; Survival Analysis; Treatment Outcome	2003
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome	2004
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-15, Volume: 10, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel	2004
A phase II study of carboplatin and paclitaxel in esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome	2004
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. International journal of radiation oncology, biology, physics, 2004, Sep-01, Volume: 60, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Survival Rate	2004
Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2004, Volume: 17, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prospective Studies; Radiation Dosage; Radiotherapy, Adjuvant; Stents; Treatment Outcome	2004
Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-15, Volume: 22, Issue:22 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome	2004
Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer investigation, 2004, Volume: 22, Issue:5 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Paclitaxel; Radiotherapy; Trastuzumab	2004
[What to expect from the neoadjuvant therapy of the oesophageal carcinoma?]. Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti, 2004, Volume: 83, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Postoperative Complications	2004
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-20, Volume: 23, Issue:6 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Analysis	2005
Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Rate; Weight Loss	2004
[Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:12 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate	2004
Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. Journal of Korean medical science, 2005, Volume: 20, Issue:4 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatigue; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting	2005
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Annals of surgical oncology, 2006, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postoperative Complications; Radiotherapy Dosage; Remission Induction; Survival Rate	2006
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Macrolides; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2006
Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. British journal of cancer, 2006, May-22, Volume: 94, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage; Survival Rate	2006
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Investigational new drugs, 2006, Volume: 24, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Macrolides; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis	2006
Pilot study of preoperative combined modality treatment for locally advanced operable oesophageal carcinoma: toxicities and long-term outcome. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:4 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Prospective Studies; Radiotherapy, Conformal; Survival Analysis	2006
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma. The Annals of thoracic surgery, 2006, Volume: 82, Issue:1 Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Combined Modality Therapy; Epoetin Alfa; Erythropoietin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hemoglobins; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Postoperative Complications; Prospective Studies; Recombinant Proteins; Stomach Neoplasms; Survival Analysis	2006
Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. American journal of clinical oncology, 2006, Volume: 29, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Polyglutamic Acid; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Stomach Neoplasms	2006
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. International journal of radiation oncology, biology, physics, 2007, Feb-01, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Female; Gene Amplification; Genes, erbB-2; Humans; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab	2007
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. International journal of radiation oncology, biology, physics, 2007, Feb-01, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage	2007
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. American journal of clinical oncology, 2006, Volume: 29, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome	2006
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. International journal of radiation oncology, biology, physics, 2007, Mar-15, Volume: 67, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage	2007
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Arthralgia; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome	2007
A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel	2007
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed	2008
Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:8 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Floxuridine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel	2007
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anti-cancer drugs, 2007, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel	2007
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma. International journal of radiation oncology, biology, physics, 2008, Mar-15, Volume: 70, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiotherapy Dosage; Tegafur; Uracil	2008
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Annals of surgical oncology, 2008, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome	2008
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). American journal of clinical oncology, 2007, Volume: 30, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Paclitaxel; Patient Selection; Radiotherapy; Recurrence; Survival Analysis; Survivors; Time Factors	2007
[Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:6 Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fatigue; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Radiotherapy; Radiotherapy, High-Energy; Survival Analysis	2007
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. International journal of radiation oncology, biology, physics, 2008, Feb-01, Volume: 70, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Drug Hypersensitivity; Esophageal Neoplasms; Esophagitis; Facial Dermatoses; Feasibility Studies; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms	2008
Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma. International journal of radiation oncology, biology, physics, 2008, May-01, Volume: 71, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Esophagectomy; Female; Health Status; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Quality of Life; Radiotherapy; Recovery of Function	2008
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel	2008
A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. American journal of clinical oncology, 2008, Volume: 31, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate	2008
Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2008, Volume: 21, Issue:7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Taxoids	2008
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome	2008
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:5 Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Survival Rate; Treatment Outcome	2008
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. Journal of surgical oncology, 2008, Jul-01, Volume: 98, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Premedication; Prognosis; Radiation Dosage; Radiotherapy, Adjuvant; Treatment Outcome	2008
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. The Annals of thoracic surgery, 2008, Volume: 85, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies	2008
A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: preliminary report. Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 8 Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Treatment Outcome	1994
Paclitaxel in the treatment of carcinoma of the esophagus. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis	1995
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. Journal of the National Cancer Institute, 1994, Jul-20, Volume: 86, Issue:14 Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome	1994
[Phase I study of paclitaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:14 Topics: Adolescent; Adult; Aged; Breast Neoplasms; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel	1994
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Seminars in oncology, 1996, Volume: 23, Issue:5 Suppl 12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms	1996
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Medical oncology (Northwood, London, England), 1996, Volume: 13, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids	1996
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. The Journal of thoracic and cardiovascular surgery, 1997, Volume: 114, Issue:5 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Survival Rate	1997
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Treatment Outcome	1997
A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome	1997
A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	1997
A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome	1997
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome	1997
Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	1997
Phase I study of docetaxel with concomitant thoracic radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Treatment Outcome	1998
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate	1998
Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy. Seminars in oncology, 1998, Volume: 25, Issue:3 Suppl 8 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids	1998
Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. British journal of cancer, 1998, Volume: 78, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel	1998
Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms	1999
Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer, 1999, Jun-01, Volume: 85, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Etoposide; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome	1999
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. British journal of cancer, 1999, Volume: 80, Issue:7 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Leukopenia; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Thrombocytopenia	1999
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome	2000
Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis; Treatment Outcome	2000
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. American journal of clinical oncology, 2000, Volume: 23, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting	2000
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. American journal of clinical oncology, 2001, Volume: 24, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy	2001
Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer investigation, 2001, Volume: 19, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate	2001
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer, 2001, Jul-15, Volume: 92, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Preoperative Care; Prognosis; Stomach Neoplasms; Survival Analysis	2001
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. British journal of cancer, 2002, Mar-04, Volume: 86, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nervous System; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome	2002
Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investigational new drugs, 2002, Volume: 20, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids	2002

Other Studies

236 other study(ies) available for paclitaxel and Cancer of Esophagus

Article	Year
Jesridonin in combination with paclitaxel demonstrates synergistic anti-tumor activity in human esophageal carcinoma cells. Bioorganic & medicinal chemistry letters, 2017, 05-01, Volume: 27, Issue:9 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Diterpenes, Kaurane; Drug Synergism; Esophageal Neoplasms; Esophagus; Humans; Paclitaxel	2017
Luteolin combined with low-dose paclitaxel synergistically inhibits epithelial-mesenchymal transition and induces cell apoptosis on esophageal carcinoma in vitro and in vivo. Phytotherapy research : PTR, 2021, Volume: 35, Issue:11 Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Humans; Luteolin; Paclitaxel	2021
Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the 'CROSS-regimen' in daily practice. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2022, Apr-19, Volume: 35, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies	2022
Luteolin attenuates cancer cell stemness in PTX-resistant oesophageal cancer cells through mediating SOX2 protein stability. Pharmacological research, 2021, Volume: 174 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Luteolin; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Stability; Proto-Oncogene Proteins c-akt; SOXB1 Transcription Factors	2021
Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade. International journal of molecular sciences, 2021, Oct-25, Volume: 22, Issue:21 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Forkhead Box Protein M1; Glycogen Synthase Kinase 3 beta; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Invasiveness; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction; Triterpenes; Ursolic Acid	2021
Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma. Biochemical and biophysical research communications, 2022, 01-01, Volume: 586 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cofilin 1; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F-Box Proteins; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Paclitaxel; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2022
Pre-operative Carboplatin/Paclitaxel Anticancer research, 2022, Volume: 42, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Retrospective Studies	2022
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022, Volume: 25, Issue:3 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Humans; Paclitaxel; Ramucirumab; Republic of Korea; Stomach Neoplasms	2022
Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study. Thoracic cancer, 2022, Volume: 13, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Epithelial Cells; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies	2022
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma. The oncologist, 2022, 02-03, Volume: 27, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Paclitaxel; Tumor Microenvironment	2022
Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. Gene therapy, 2023, Volume: 30, Issue:1-2 Topics: B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Exosomes; Humans; MicroRNAs; Paclitaxel; STAT3 Transcription Factor	2023
Chemotherapy-Induced Myelosuppression in Esophageal Cancer Patients: Risks and Suggestions for Its Management. Current medical science, 2022, Volume: 42, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Humans; Paclitaxel; Retrospective Studies; Uric Acid	2022
Urolithins increased anticancer effects of chemical drugs, ionizing radiation and hyperthermia on human esophageal carcinoma cells in vitro. Tissue & cell, 2022, Volume: 77 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; HSP27 Heat-Shock Proteins; Humans; Hyperthermia, Induced; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Radiation, Ionizing	2022
Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China. Frontiers in public health, 2022, Volume: 10 Topics: Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Nivolumab; Paclitaxel	2022
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. PharmacoEconomics, 2022, Volume: 40, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cost-Benefit Analysis; Delivery of Health Care; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Platinum; Quality-Adjusted Life Years; Trastuzumab	2022
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis. Radiation oncology (London, England), 2022, Nov-17, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Retrospective Studies	2022
Paclitaxel-resistant related lncRNA DBH-AS1 promotes the proliferation and invasion of esophageal cancer. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:23 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; RNA, Long Noncoding	2022
Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study. Radiation oncology (London, England), 2022, Dec-30, Volume: 17, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies	2022
Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma. Advances in therapy, 2023, Volume: 40, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years	2023
Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma. Thoracic cancer, 2023, Volume: 14, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome	2023
YAP inhibitor verteporfin suppresses tumor angiogenesis and overcomes chemoresistance in esophageal squamous cell carcinoma. Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10 Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neovascularization, Pathologic; Paclitaxel; Verteporfin	2023
Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis. Cancer medicine, 2023, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Liposomes; Paclitaxel; Retrospective Studies	2023
Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma. European journal of cancer (Oxford, England : 1990), 2023, Volume: 186 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor	2023
The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. PloS one, 2023, Volume: 18, Issue:5 Topics: Antineoplastic Agents, Immunological; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Nutritional Status; Paclitaxel; Retrospective Studies	2023
Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer. Future oncology (London, England), 2023, Volume: 19, Issue:18 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Humans; Immune Checkpoint Inhibitors; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms	2023
Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2023, Oct-27, Volume: 36, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cost-Effectiveness Analysis; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies	2023
Chloroquine Sensitizes Esophageal Carcinoma EC109 Cells to Paclitaxel by Inhibiting Autophagy. Critical reviews in eukaryotic gene expression, 2023, Volume: 33, Issue:6 Topics: Apoptosis; Autophagy; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chloroquine; Esophageal Neoplasms; Humans; Paclitaxel; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases	2023
Paclitaxel promotes mTOR signaling-mediated apoptosis in esophageal cancer cells by targeting MUC20. Thoracic cancer, 2023, Volume: 14, Issue:31 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Esophageal Neoplasms; Humans; Mice; Mice, Nude; Mucins; Paclitaxel; TOR Serine-Threonine Kinases	2023
PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway/ferroptosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 168 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Ferroptosis; Humans; Mice; NADP; Paclitaxel; Pentose Phosphate Pathway; Polo-Like Kinase 1; YY1 Transcription Factor	2023
Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction - comparison of postoperative mortality and complications, toxicity, and pathologic Langenbeck's archives of surgery, 2023, Nov-08, Volume: 408, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials as Topic; Esophageal Neoplasms; Esophagogastric Junction; Humans; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies	2023
Dual-Functional Esophageal Stent Coating Composed of Paclitaxel-Loaded Electrospun Membrane and Protective Film. Journal of biomedical nanotechnology, 2019, Oct-01, Volume: 15, Issue:10 Topics: Animals; Drug Delivery Systems; Esophageal Neoplasms; Humans; Paclitaxel; Quality of Life; Stents	2019
Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-20, Volume: 37, Issue:30 Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Taxoids	2019
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma. Radiation oncology (London, England), 2019, Sep-18, Volume: 14, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Salvage Therapy; Survival Rate	2019
Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study. Annals of surgery, 2021, 12-01, Volume: 274, Issue:6 Topics: Adult; Aged; Carboplatin; Chemoradiotherapy; Endosonography; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron Emission Tomography Computed Tomography; Postoperative Complications; Propensity Score; Prospective Studies; Reoperation; Watchful Waiting	2021
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma. Scientific reports, 2019, 11-26, Volume: 9, Issue:1 Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays	2019
Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer. European radiology, 2020, Volume: 30, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Prospective Studies; Time Factors; Treatment Outcome; Tumor Burden	2020
Intensified Neoadjuvant Chemoradiotherapy for Patients with Potentially Resectable Esophageal Cancer: A Retrospective Cohort Study. Annals of surgical oncology, 2020, Volume: 27, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Netherlands; Paclitaxel; Retrospective Studies; Survival Rate	2020
Complete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction Cancer. Clinical nuclear medicine, 2020, Volume: 45, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Ramucirumab	2020
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. Oncology reports, 2020, Volume: 43, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Niclosamide; Paclitaxel; Signal Transduction; STAT3 Transcription Factor	2020
Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Retrospective Studies; Survival Analysis; Treatment Outcome	2020
Removal of tumor thrombus from the azygos vein in an esophageal squamous cell carcinoma patient. Journal of cardiothoracic surgery, 2020, Mar-26, Volume: 15, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Azygos Vein; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Thrombosis	2020
A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Humans; Logistic Models; Male; Middle Aged; Netherlands; Paclitaxel; Propensity Score; Proportional Hazards Models; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome	2020
Morphine Stimulates Migration and Growth and Alleviates the Effects of Chemo Drugs via AMPK-Dependent Induction of Epithelial-Mesenchymal Transition in Esophageal Carcinoma Cells. Biological & pharmaceutical bulletin, 2020, Volume: 43, Issue:5 Topics: AMP-Activated Protein Kinases; Analgesics, Opioid; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Antagonism; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Fluorouracil; Humans; Morphine; Paclitaxel; rac1 GTP-Binding Protein; Reactive Oxygen Species; rhoA GTP-Binding Protein	2020
Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PloS one, 2020, Volume: 15, Issue:5 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Cost-Benefit Analysis; Esophageal Neoplasms; Female; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Paclitaxel; Progression-Free Survival; Quality of Life; Quality-Adjusted Life Years; Ramucirumab; Stomach; Stomach Neoplasms	2020
Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI. Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Time Factors; Tumor Burden	2020
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma. Advances in therapy, 2020, Volume: 37, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; United States	2020
Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer. Fundamental & clinical pharmacology, 2021, Volume: 35, Issue:1 Topics: Animals; Anthelmintics; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Niclosamide; Paclitaxel; Wnt Signaling Pathway	2021
Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer medicine, 2020, Volume: 9, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Young Adult	2020
Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-matched Study. Annals of surgery, 2020, Volume: 272, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Propensity Score; Retrospective Studies	2020
Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study. European journal of cancer (Oxford, England : 1990), 2020, Volume: 139 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Esophageal Neoplasms; Esophagogastric Junction; Female; Hospitalization; Hospitals, High-Volume; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Paclitaxel; Palliative Care; Ramucirumab; Stomach Neoplasms; Taxoids	2020
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. Oncology, 2021, Volume: 99, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Stomach Neoplasms	2021
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. Cancer medicine, 2021, Volume: 10, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cohort Studies; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Survival Rate	2021
Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Paclitaxel; Progression-Free Survival; Radiotherapy; Retrospective Studies; Salvage Therapy; Time Factors	2021
Outcomes of Ramucirumab Plus Paclitaxel Among Patients With Previously Treated Metastatic Gastric/Lower Esophageal Cancer: A Real-world Study. American journal of clinical oncology, 2021, 04-01, Volume: 44, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Palliative Care; Ramucirumab; Retrospective Studies; Stomach Neoplasms	2021
Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma. Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:9 Topics: Afatinib; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Mice; Paclitaxel; Phosphorylation; Xenograft Model Antitumor Assays	2021
Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:10 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Humans; Length of Stay; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Compliance; Postoperative Complications; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Time Factors	2021
Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2021, Volume: 25, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Liposomes; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Radiotherapy, Intensity-Modulated	2021
A Canadian single institution real-world experience using the CROSS trial regimen in the treatment of oesophageal and gastroesophageal junction carcinoma. Internal medicine journal, 2022, Volume: 52, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Chemoradiotherapy; Clinical Trial Protocols as Topic; Esophageal Neoplasms; Esophagogastric Junction; Humans; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies	2022
MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel. Bioengineered, 2021, Volume: 12, Issue:1 Topics: Adult; Aged; Animals; Arrestins; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Nude; MicroRNAs; Middle Aged; Paclitaxel; YAP-Signaling Proteins	2021
Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727. Oncology reports, 2017, Volume: 37, Issue:4 Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mitochondria; Paclitaxel; Phosphorylation; Serine; STAT3 Transcription Factor	2017
Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Apr-01, Volume: 30, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Outcome	2017
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Annals of surgical oncology, 2017, Volume: 24, Issue:8 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Perioperative Care; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate	2017
Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists. Oncotarget, 2017, May-23, Volume: 8, Issue:21 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; China; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Four-Dimensional Computed Tomography; Humans; Lymphatic Metastasis; Paclitaxel; Postoperative Care; Practice Patterns, Physicians'; Preoperative Care; Radiation Oncologists; Radiotherapy Planning, Computer-Assisted; Surveys and Questionnaires	2017
Adenocarcinoma of the appendix occurring in a patient treated with paclitaxel for locally advanced esophageal cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:2 Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Esophageal Neoplasms; Humans; Male; Neoplasms, Second Primary; Paclitaxel	2018
Remission Following Paclitaxel and Cisplatin Treatment in a 15-Year-Old Patient With Unresectable Esophageal Squamous Cell Cancer. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Humans; Male; Paclitaxel; Remission Induction	2017
Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 90 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2	2017
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Jul-01, Volume: 30, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome	2017
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Jul-01, Volume: 30, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Readmission; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Young Adult	2017
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. Digestive surgery, 2018, Volume: 35, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids	2018
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. Journal of translational medicine, 2017, 06-02, Volume: 15, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; G1 Phase Cell Cycle Checkpoints; Humans; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Xenograft Model Antitumor Assays	2017
Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer. Cancer science, 2017, Volume: 108, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Treatment Outcome	2017
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. American journal of clinical oncology, 2018, Volume: 41, Issue:9 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome	2018
Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers. Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel	2017
Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Sep-01, Volume: 30, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Neoplasm Staging; Paclitaxel; Patient Compliance; Propensity Score; Radiotherapy, Conformal; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate	2017
Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer. International journal of radiation oncology, biology, physics, 2017, 11-15, Volume: 99, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chi-Square Distribution; Cisplatin; Deglutition Disorders; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Propensity Score; Regression Analysis; Retrospective Studies; Stents; Treatment Outcome	2017
Bilateral Adrenalectomy for Metastatic Esophageal Adenocarcinoma: A Case Report. Journal of oncology practice, 2018, Volume: 14, Issue:1 Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Hormone Replacement Therapy; Humans; Liver Neoplasms; Male; Paclitaxel	2018
Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report. BMC cancer, 2017, Nov-07, Volume: 17, Issue:1 Topics: Carcinoma in Situ; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Lymph Node Excision; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome	2017
Selective anticancer activity of the novel steroidal dihydropyridine spirooxindoles against human esophageal EC109 cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 96 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Dihydropyridines; Drug Resistance; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Small Molecule Libraries	2017
[A Case of Liver Metastasis from Esophageal Cancer Successfully Treated by Surgical Resection after Chemotherapy with Weekly-Paclitaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis	2017
Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells. Cancer letters, 2018, 04-28, Volume: 420 Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Mice; Neoplasm Transplantation; Paclitaxel; Proteasome Endopeptidase Complex; Sequence Analysis, RNA; Single-Cell Analysis	2018
Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Esophageal Neoplasms; Esophagectomy; Female; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Netherlands; Paclitaxel; Propensity Score; Registries; Retrospective Studies; Treatment Outcome	2018
Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. JAMA oncology, 2018, 06-01, Volume: 4, Issue:6 Topics: Cetuximab; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Humans; Paclitaxel	2018
Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. JAMA oncology, 2018, 06-01, Volume: 4, Issue:6 Topics: Cetuximab; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Humans; Paclitaxel	2018
Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer-Reply. JAMA oncology, 2018, 06-01, Volume: 4, Issue:6 Topics: Cetuximab; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Humans; Paclitaxel	2018
Animal Model: Xenograft Mouse Models in Esophageal Adenocarcinoma. Methods in molecular biology (Clifton, N.J.), 2018, Volume: 1756 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays	2018
Totally minimally invasive esophagectomy after neoadjuvant chemoradiotherapy: Long-term oncologic outcomes. Journal of surgical oncology, 2018, Volume: 117, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Paclitaxel; Positron Emission Tomography Computed Tomography; Postoperative Complications; Retrospective Studies; Treatment Outcome	2018
Natural Borneol Enhances Paclitaxel-Induced Apoptosis of ESCC Cells by Inactivation of the PI3K/AKT. Journal of food science, 2018, Volume: 83, Issue:5 Topics: Apoptosis; Camphanes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt	2018
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. The oncologist, 2018, Volume: 23, Issue:7 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Ramucirumab; Stomach Neoplasms	2018
Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery : Long-term results. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2018, Volume: 194, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Prognosis; Survival Rate	2018
A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas. PloS one, 2018, Volume: 13, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Autophagy; Biopsy; Disease-Free Survival; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Microtubule-Associated Proteins; Middle Aged; Neoadjuvant Therapy; Paclitaxel; RNA-Binding Proteins; Transcription Factors	2018
Association of serum annexin A1 with treatment response and prognosis in patients with esophageal squamous cell carcinoma. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement Topics: Adult; Aged; Annexin A1; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; MicroRNAs; Middle Aged; Paclitaxel; Prognosis	2018
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. Anticancer research, 2018, Volume: 38, Issue:10 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tertiary Care Centers	2018
Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. Journal of biomaterials applications, 2018, Volume: 33, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; ErbB Receptors; Erythrocyte Membrane; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Humans; Immunoconjugates; Oligopeptides; Paclitaxel; Radiation-Sensitizing Agents; Recombinant Proteins	2018
Underutilization of the CROSS Regimen Among US Radiation Oncologists: A National Survey of Practice Patterns. Anticancer research, 2018, Volume: 38, Issue:11 Topics: Carboplatin; Chemoradiotherapy; Clinical Trials as Topic; Esophageal Neoplasms; Female; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Practice Patterns, Physicians'; Radiation Oncologists; Radiotherapy Dosage; Surveys and Questionnaires	2018
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study. Radiation oncology (London, England), 2018, Nov-26, Volume: 13, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult	2018
Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study. Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:4 Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Osteonectin; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Tubulin	2019
Accuracy of 3-T MRI for Preoperative T Staging of Esophageal Cancer After Neoadjuvant Chemotherapy, With Histopathologic Correlation. AJR. American journal of roentgenology, 2019, Volume: 212, Issue:4 Topics: Adult; Aged; Chemotherapy, Adjuvant; Contrast Media; Esophageal Neoplasms; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Prospective Studies	2019
Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology, 2019, Volume: 96, Issue:5 Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Ramucirumab; Retrospective Studies; Treatment Outcome	2019
Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. The oncologist, 2019, Volume: 24, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Skin Diseases	2019
Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma. International journal of cancer, 2019, 11-15, Volume: 145, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Chemoradiotherapy; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Esophageal Mucosa; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Primary Cell Culture; Progression-Free Survival; Signal Transduction; Transforming Growth Factor beta; Treatment Outcome; Xenograft Model Antitumor Assays	2019
Reply to A. Adenis et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 09-10, Volume: 37, Issue:26 Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel	2019
Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer: A Matter of Standard. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 09-10, Volume: 37, Issue:26 Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel	2019
Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. Journal of global oncology, 2019, Volume: 5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Esophageal Neoplasms; Hospitals, Community; Humans; Irinotecan; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome	2019
RNAi-induced K-Ras gene silencing suppresses growth of EC9706 cells and enhances chemotherapy sensitivity of esophageal cancer. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:12 Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Esophageal Neoplasms; Gene Silencing; Genes, ras; Humans; Paclitaxel; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection	2012
Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma. Radiation oncology (London, England), 2013, Mar-27, Volume: 8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy, Intensity-Modulated; Retrospective Studies	2013
Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Radiotherapy; Retrospective Studies; Survival Rate; Young Adult	2013
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:3 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden	2014
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. Annals of surgical oncology, 2013, Volume: 20, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate	2013
Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line. International journal of oncology, 2013, Volume: 43, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Caspase 3; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured	2013
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy. Anticancer research, 2013, Volume: 33, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids	2013
Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Annals of surgery, 2013, Volume: 258, Issue:5 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Mucous Membrane; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Paclitaxel; Treatment Outcome	2013
Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. Annals of surgical oncology, 2014, Volume: 21, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonia; Postoperative Complications; Prognosis; Prospective Studies; Survival Rate; Thoracotomy	2014
Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt. Oncology reports, 2014, Volume: 31, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 7; Caspase 9; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; M Phase Cell Cycle Checkpoints; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53	2014
[Analysis of weekly paclitaxel chemotherapy for esophageal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome	2013
Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer. International journal of radiation oncology, biology, physics, 2014, Mar-15, Volume: 88, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Prospective Studies; Radiography; Radiotherapy Planning, Computer-Assisted; Regression Analysis; Tumor Burden	2014
Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients. American journal of surgery, 2014, Volume: 208, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Disease Progression; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Preoperative Care; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome	2014
Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. BMC cancer, 2014, Jan-31, Volume: 14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Odds Ratio; Paclitaxel; Patient Admission; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2014
A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome; Tubulin Modulators	2014
Increased risk of thromboembolism in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. American journal of surgery, 2014, Volume: 208, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carboplatin; Chemoradiotherapy; Endosonography; Esophageal Neoplasms; Esophagectomy; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage; Thromboembolism	2014
Paclitaxel-based regimens as first-line treatment in advanced gastric cancer. Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; China; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Incidence; Leukopenia; Male; Medical Records; Middle Aged; Neoplasm Grading; Paclitaxel; Prevalence; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Analysis	2015
Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma. World journal of surgical oncology, 2014, Feb-25, Volume: 12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Follow-Up Studies; Hematologic Tests; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies	2014
High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy. Annals of surgical oncology, 2014, Volume: 21, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Survival Rate; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A	2014
Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2015, Volume: 28, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Female; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Outcome; Young Adult	2015
[Value of postoperative radiochemotherapy for thoracic esophageal squamous cell carcinoma with lymph node metastasis]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagitis; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Particle Accelerators; Postoperative Period; Retrospective Studies; Survival Rate	2014
Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2015, Volume: 28, Issue:7 Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Remission Induction; Retrospective Studies; Taxoids	2015
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? Journal of surgical oncology, 2014, Volume: 110, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms	2014
Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids	2014
A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer. Anti-cancer drugs, 2015, Volume: 26, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Paclitaxel; Retrospective Studies	2015
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2014
Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Down-Regulation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Male; MicroRNAs; Middle Aged; Paclitaxel; Predictive Value of Tests	2014
siRNA blocking the RAS signalling pathway and inhibits the growth of oesophageal squamous cell carcinoma in nude mice. Cell biochemistry and function, 2014, Volume: 32, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; Cyclin D1; Drug Resistance; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Heterografts; Male; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; ras Proteins; RNA, Small Interfering; Signal Transduction	2014
Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel. Cancer gene therapy, 2015, Volume: 22, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Shape; Cell Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Humans; Paclitaxel; RNA Interference; RNA, Small Interfering; Stathmin	2015
Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015, Volume: 114, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Carboplatin; Cardiac Volume; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Radiation Dosage; Radiotherapy Dosage	2015
Clozapine and concomitant chemotherapy in a patient with schizophrenia and new onset esophageal cancer. Psycho-oncology, 2015, Volume: 24, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Carboplatin; Carcinoma, Squamous Cell; Clozapine; Esophageal Neoplasms; Humans; Male; Neutropenia; Paclitaxel; Schizophrenia	2015
Pathologic response during chemo-radiotherapy and variation of serum VEGF levels could predict effects of chemo-radiotherapy in patients with esophageal cancer. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vascular Endothelial Growth Factor A	2015
Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy. Radiation oncology (London, England), 2015, Mar-06, Volume: 10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Complications; Prognosis; Radiotherapy Dosage; Survival Rate	2015
Paclitaxel or 5-fluorouracil/esophageal stent combinations as a novel approach for the treatment of esophageal cancer. Biomaterials, 2015, Volume: 53 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Stents; Swine; Tissue Distribution	2015
CT Signs Can Predict Treatment Response and Long-Term Survival: A Study in Locally Advanced Esophageal Cancer with Preoperative Chemotherapy. Annals of surgical oncology, 2015, Volume: 22 Suppl 3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed	2015
Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:10 Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Esophageal Neoplasms; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stathmin; Tubulin Modulators; Tumor Cells, Cultured; Vinblastine; Xenograft Model Antitumor Assays	2015
Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016, Volume: 29, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome	2016
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer? European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Diabetes Mellitus, Type 2; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hypoglycemic Agents; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome	2015
[Inhibitory effect of 17-AAG combined with paclitaxel on proliferation of esophageal squamous cell carcinoma Eca-109 cells in vitro]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2015, Volume: 35, Issue:6 Topics: Apoptosis; Benzoquinones; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lactams, Macrocyclic; Paclitaxel	2015
Clinical Research on Albumin-Bound Paclitaxel-Based Chemotherapy for Advanced Esophageal Cancer. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:12 Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel	2015
Retrospective Study of Adjuvant Chemotherapy Effects on Survival Rate after Three-Field Lymph Node Dissection for Stage IIA Esophageal Cancer. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids	2015
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Paclitaxel; Peptide Initiation Factors; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Taxoids	2015
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. Annals of surgical oncology, 2015, Volume: 22 Suppl 3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate	2015
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. Oncotarget, 2016, Jan-19, Volume: 7, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; China; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genomics; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured	2016
Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma. World journal of surgical oncology, 2015, Nov-09, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; China; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; STAT3 Transcription Factor; Treatment Outcome	2015
Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling. Oncotarget, 2016, Jan-26, Volume: 7, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2016
Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells. International journal of oncology, 2016, Volume: 48, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; DNA Breaks, Double-Stranded; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Taxoids	2016
Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel. Genetics and molecular research : GMR, 2015, Dec-29, Volume: 14, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Expression; Gene Silencing; Humans; Paclitaxel; RNA, Messenger; RNA, Small Interfering; Stathmin; Transfection	2015
[A Case of Lymph Node Metastases from Esophageal Cancer Successfully Treated with Weekly Paclitaxel Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Esophageal Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence	2015
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma. Chemotherapy, 2016, Volume: 61, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome	2016
Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer. Oncology research, 2016, Volume: 23, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Treatment Outcome; Young Adult	2016
Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Complications; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Treatment Outcome	2016
Potential of Baseline Computed Tomography to Predict Long-Term Survival of Patients With Locally Advanced Esophageal Cancer Treated With Preoperative Chemotherapy: A Retrospective Cohort Study. Medicine, 2016, Volume: 95, Issue:18 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Tumor Burden	2016
Auraptene Attenuates Malignant Properties of Esophageal Stem-Like Cancer Cells. Technology in cancer research & treatment, 2017, Volume: 16, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Coumarins; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Gene Expression; Humans; Hyaluronan Receptors; Inhibitory Concentration 50; Neoplastic Stem Cells; Paclitaxel; Polycomb Repressive Complex 1; Tumor Suppressor Protein p53	2017
Study of single nucleotide polymorphisms of FBW7 and its substrate genes revealed a predictive factor for paclitaxel plus cisplatin chemotherapy in Chinese patients with advanced esophageal squamous cell carcinoma. Oncotarget, 2016, Jul-12, Volume: 7, Issue:28 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F-Box-WD Repeat-Containing Protein 7; Female; Genotype; Humans; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies	2016
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. Drug design, development and therapy, 2016, Volume: 10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Young Adult	2016
Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer. BMJ case reports, 2016, Aug-18, Volume: 2016 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Humans; Hypertension; Infusions, Intravenous; Male; Paclitaxel; Ramucirumab; Stomach Neoplasms; Vascular Endothelial Growth Factor A	2016
Impact of the radiotherapy combined with cisplatin plus paclitaxel chemotherapy on the immunologic functions in the patients with esophageal cancer. Pakistan journal of pharmaceutical sciences, 2016, Volume: 29, Issue:4 Suppl Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Humans; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Paclitaxel; Survival Analysis; T-Lymphocytes; Taxoids; Th17 Cells	2016
Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, 02-01, Volume: 30, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophagus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult	2017
[Second-line treatment for metastatic or locally advanced gastric cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, Oct-23, Volume: 38, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Molecular Targeted Therapy; Paclitaxel; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Taxoids	2016
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. Oncotarget, 2017, Jan-31, Volume: 8, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cisplatin; Disease Progression; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Tegafur; Time Factors; Treatment Outcome	2017
[A Case of Heterochronic Cervical Esophageal Cancer with a Subcutaneous Abscess Showing a Complete Response to Chemoradiation Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Abscess; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Male; Paclitaxel; Stomach Neoplasms	2016
Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells. International journal of molecular medicine, 2017, Volume: 39, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Mice; Neoplastic Stem Cells; Paclitaxel; Xenograft Model Antitumor Assays	2017
A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma. PloS one, 2017, Volume: 12, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease Models, Animal; Esophageal Neoplasms; Heterografts; Mice; Neoplasm Transplantation; Paclitaxel; Peritoneal Neoplasms	2017
The effect of paclitaxel-eluting covered metal stents versus covered metal stents in a rabbit esophageal squamous carcinoma model. PloS one, 2017, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug-Eluting Stents; Esophageal Neoplasms; Female; Male; Paclitaxel; Rabbits	2017
The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies	2017
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival. Journal of surgical oncology, 2017, Volume: 115, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism	2017
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer, 2008, Sep-15, Volume: 113, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Preoperative Care; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome	2008
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:11 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed	2008
[Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma]. Zhonghua yi xue za zhi, 2008, Aug-12, Volume: 88, Issue:31 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Radiotherapy; Young Adult	2008
Preoperative chemoradiation combined with regional hyperthermia for patients with resectable esophageal cancer. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:1 Topics: Aged; Antineoplastic Agents; Carboplatin; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome	2009
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. Journal of experimental & clinical cancer research : CR, 2009, May-27, Volume: 28 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Doxorubicin; Drug Resistance, Neoplasm; Esophageal Neoplasms; Etoposide; Fluorouracil; Humans; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured; X-Rays	2009
Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement. Journal of surgical oncology, 2009, Oct-01, Volume: 100, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Squamous Cell; Celiac Plexus; Cisplatin; Databases, Factual; Esophageal Neoplasms; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Laparoscopy; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Retrospective Studies	2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate	2010
[A case showing a complete response by weekly paclitaxel associated with severe empyema and mediastinal abscess caused by reduction of a recurrent lung metastatic tumor originating from adenocarcinoma of the esophagogastric junction after primary operatio Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents; Empyema, Pleural; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Gastrectomy; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Tomography, X-Ray Computed	2010
Chemoradiation for esophageal cancer: institutional experience with three different regimens. American journal of clinical oncology, 2011, Volume: 34, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome	2011
[Inhibitory effect of photodynamic therapy combined with paclitaxel on the proliferation of esophageal carcinoma Eca-109 cells]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Humans; Paclitaxel; Photochemotherapy	2010
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Contrast Media; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome	2010
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Annals of surgical oncology, 2011, Volume: 18, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Introns; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Survival Rate	2011
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. International journal of radiation oncology, biology, physics, 2011, Nov-15, Volume: 81, Issue:4 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Irradiation; Male; Middle Aged; Paclitaxel; Preoperative Care; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Failure	2011
Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2012, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Preoperative Period; Remission Induction; Survival Analysis; Treatment Outcome	2012
Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. International journal of oncology, 2011, Volume: 39, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor Proteins; Esophageal Neoplasms; Humans; Paclitaxel; Signal Transduction; Tumor Suppressor Protein p53	2011
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:10 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed	2011
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology, 2011, Volume: 81, Issue:3-4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids	2011
[A case of lung resection after chemotherapy due to lung metastases derived from esophageal cancer resection]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Biopsy; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Tomography, X-Ray Computed	2011
Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells. Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:7 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cisplatin; Colony-Forming Units Assay; Drug Resistance; Esophageal Neoplasms; Gene Expression; Humans; Neoplasms, Radiation-Induced; Paclitaxel; Radiation Tolerance; RNA, Messenger; Up-Regulation; Verapamil	2012
Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. Radiation oncology (London, England), 2012, Jun-19, Volume: 7 Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome	2012
Antitumor activity of folate-targeted, paclitaxel-loaded polymeric micelles on a human esophageal EC9706 cancer cell line. International journal of nanomedicine, 2012, Volume: 7 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Carriers; Esophageal Neoplasms; Flow Cytometry; Folic Acid; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Male; Mice; Mice, Nude; Micelles; Nanoconjugates; Paclitaxel; Xenograft Model Antitumor Assays	2012
Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2013, Volume: 26, Issue:5 Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Hematologic Diseases; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Survival Rate	2013
Moderately hypofractionated conformal radiation treatment of thoracic esophageal carcinoma. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Thoracic Neoplasms	2012
The 2002 AJCC TNM classification is a better predictor of primary small cell esophageal carcinoma outcome than the VALSG staging system. Chinese journal of cancer, 2013, Volume: 32, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Etoposide; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, High-Energy; Retrospective Studies; Societies, Medical; Survival Rate; United States	2013
Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells. Cancer biology & therapy, 2013, Volume: 14, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Cyclin B1; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Knockdown Techniques; Humans; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction	2013
Abnormal expression of the mitotic checkpoint protein BubR1 contributes to the anti-microtubule drug resistance of esophageal squamous cell carcinoma cells. Oncology reports, 2013, Volume: 29, Issue:1 Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Female; Humans; Male; Middle Aged; Mitotic Index; Neoplasm Staging; Nocodazole; Paclitaxel; Prognosis; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tubulin Modulators; Tumor Cells, Cultured	2013
Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma. Oncology reports, 2013, Volume: 29, Issue:2 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Chi-Square Distribution; Esophageal Neoplasms; Female; Gene Knockdown Techniques; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Phosphorylation; RNA, Small Interfering; Stathmin; Tubulin Modulators; Wound Healing	2013
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. Annals of surgical oncology, 2013, Volume: 20, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Confidence Intervals; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Survival Rate; Tumor Burden	2013
Is preoperative chemoradiation with paclitaxel and carboplatin a new standard of treatment for esophageal cancer? International journal of radiation oncology, biology, physics, 2013, May-01, Volume: 86, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Clinical Trials as Topic; Esophageal Neoplasms; Humans; Paclitaxel; Preoperative Care; Radiation Pneumonitis; Treatment Outcome	2013
GPC Biotech receives Orphan Medicinal Product Designation. Expert review of anticancer therapy, 2002, Volume: 2, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biotechnology; Bryostatins; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Design; Esophageal Neoplasms; European Union; Humans; Lactones; Macrolides; Paclitaxel; United States	2002
Re: Folliculitis associated with weekly paclitaxel treatment. Journal of the National Cancer Institute, 2003, Mar-05, Volume: 95, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Administration Schedule; ErbB Receptors; Esophageal Neoplasms; Folliculitis; Humans; Male; Middle Aged; Paclitaxel	2003
The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. Clinical oncology (Royal College of Radiologists (Great Britain)), 2003, Volume: 15, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Heart; Humans; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Stroke Volume	2003
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer, 2003, Aug-01, Volume: 98, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas	2003
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome	2003
96-hour paclitaxel infusions: at least 93 hours too long. Cancer investigation, 2003, Volume: 21, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; Infusions, Intravenous; Paclitaxel; Reproducibility of Results	2003
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Stomach Neoplasms	2003
Combined modality therapy in esophageal cancer: the Memorial experience. Seminars in surgical oncology, 2003, Volume: 21, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel	2003
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. The Journal of thoracic and cardiovascular surgery, 2004, Volume: 127, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chromones; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Esophageal Neoplasms; Humans; Lung Neoplasms; Morpholines; NF-kappa B; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Statistics as Topic; Time Factors; Treatment Failure; Tumor Cells, Cultured	2004
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer, 2004, Jun-01, Volume: 100, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Survival Rate	2004
Esophageal cancer: outcomes of surgery, neoadjuvant chemotherapy, and three-dimension conformal radiotherapy. Journal of surgical oncology, 2004, Aug-01, Volume: 87, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Treatment Outcome	2004
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. International journal of radiation oncology, biology, physics, 2004, Oct-01, Volume: 60, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome	2004
[Clinical observation of TP regiment for treating refractory and terminal squamous cancer of the esophagus]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2004, Volume: 24, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome	2004
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids	2005
[A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Radiotherapy Dosage; Remission Induction	2005
Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Fragmentation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; G2 Phase; Humans; Paclitaxel; Time Factors; Tubulin Modulators	2006
Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-15, Volume: 11, Issue:20 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Calmodulin-Binding Proteins; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Time Factors; Treatment Outcome	2005
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel. International journal of clinical oncology, 2005, Volume: 10, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Humans; Liver Neoplasms; Male; Paclitaxel; Salvage Therapy; Tomography, X-Ray Computed	2005
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous	2006
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. International journal of radiation oncology, biology, physics, 2006, Jul-15, Volume: 65, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies	2006
Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2006, Volume: 22, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiotherapy; Sensitivity and Specificity; Treatment Outcome	2006
[A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Humans; Kidney Neoplasms; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Paclitaxel; Quality of Life	2006
[Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis]. Verhandlungen der Deutschen Gesellschaft fur Pathologie, 2004, Volume: 88 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; DNA Primers; Esophageal Neoplasms; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Neoadjuvant Therapy; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction	2004
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World journal of gastroenterology, 2006, Sep-14, Volume: 12, Issue:34 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Retrospective Studies	2006
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer biology & therapy, 2007, Volume: 6, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein	2007
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. International journal of radiation oncology, biology, physics, 2007, Nov-01, Volume: 69, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies	2007
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:10 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cardia; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagus; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Stents; Stomach Neoplasms; Tegafur	2007
[A case of thoracic esophageal cancer with invasion of the main bronchus in which long-term survival with high quality of life was achieved through chemoradiotherapy, esophageal bypass and then additional chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Quality of Life	2007
Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Esophageal Neoplasms; Female; Fluorouracil; Humans; Incidence; Male; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome; United States	2008
[Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Particle Accelerators; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction; Survival Rate; Thrombocytopenia	2007
Paclitaxel: current developmental approaches of the National Cancer Institute. Seminars in oncology, 1995, Volume: 22, Issue:6 Suppl 15 Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Esophageal Neoplasms; Female; Germinoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Ovarian Neoplasms; Paclitaxel; Sarcoma, Kaposi; United States; Urinary Bladder Neoplasms	1995
GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene, 1997, Volume: 15, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; Doxycycline; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Membrane Proteins; Neoplasm Proteins; Paclitaxel; Tumor Cells, Cultured	1997
Multimodality therapy of esophageal cancer. Chest, 1999, Volume: 116, Issue:6 Suppl Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate	1999
Cytology of small-cell carcinoma arising in Barrett's esophagus. Diagnostic cytopathology, 2000, Volume: 23, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cytodiagnosis; Esophageal Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome	2000
Preoperative chemoradiotherapy using taxanes for locally advanced esophageal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Reproducibility of Results; Treatment Outcome	2001
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anti-cancer drugs, 2001, Volume: 12, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine	2001
Squamous syringometaplasia associated with docetaxel. The British journal of dermatology, 2002, Volume: 146, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Metaplasia; Middle Aged; Necrosis; Paclitaxel; Sweat Gland Neoplasms; Sweat Glands; Taxoids	2002